

# 第2日

2月23日(金)

D A Y 2

Friday, February 23, 2024

## ASCO/JSMO Joint Symposium

**AJS** Drugging the Undruggable Targets ..... 202

## Asia-Pacific/JSMO Joint Symposium

**APJS** Education for Oncologists ..... 216

## Joint Symposium

**J55** Cancer Genome Medicine-Harmony for patients

がんゲノム医療－医師・看護師の協働でより良いがんゲノム医療を患者に－ ..... 204

**J56** Cancer precision medicine and multi-gene panel testing

多遺伝子パネル検査 (MGPT) の実地臨床導入に関する課題 ..... 205

## Presidential Symposium

**PSY4** Fostering the Future of Clinical Oncology through Multidisciplinary Collaboration

多学際領域との協働で奏でる臨床腫瘍学の未来 ..... 195

**PSY5** What should Japan do about cancer care in a super-aging society?

超高齢社会のがん医療、日本はどうすべきか ..... 199

## Symposium

**SY12** Treatment Strategy of Cure for Patients with Thoracic Cancer ..... 196

**SY13** UC medical oncology update: Know the true value of IO!

尿路上皮癌薬物療法最前線：IOの真価を問う！ ..... 198

**SY14** Precision medicine for colorectal cancer ..... 199

**SY15** Secure the safety of anti-cancer drug administration - Device selection, Extravasation and Phlebitis

抗がん剤を安全に投与する～デバイス選択、血管外漏出・静脈炎に取り組む～ ..... 201

**SY16** Next Stage of PPI (Patient and Public Involvement) in Japan- Involvement at the stage of regulatory approval and social implementation

日本におけるPPI(患者・市民参画)のNext Stage ～当局承認から社会実装段階での関与 ..... 202

**SY17** Let's understand clinical trial results more deeper: Discussion with statistical and economical experts

臨床試験結果の深掘り：生物統計と医療経済の専門家を交えて ..... 214

**SY18** Current status of head and neck cancer treatment aiming at personalized medicine and the future of new technology development

個別化医療を目指す頭頸部がん診療の現状と新規技術開発のゆくえ ..... 215

**SY19** Genomic medicine and novel therapeutic strategy in blood cancer

血液がんゲノム医療と新規分子標的治療 ..... 218

<b>SY20</b>	Treatment development for rare cancers 希少がんの希少フラクションとしての治療開発	218
<b>SY21</b>	Challenge and Perspective of treatment in the field of gynecologic oncology 婦人科がん領域の薬物療法の展望	219
<b>SY22</b>	How far can we go? Palliative and end-of-life care at home ここまでできる！どこまでできる？在宅緩和・終末期医療を考える	230

Committee Program

<b>CP3</b>	Is Oncology Not Popular? Discussing the reality of medical school education 【JSMO University】 腫瘍学は人気がないのか？医学部教育の実態に迫る 【JSMO University】	214
<b>CP4</b>	Oncology Education Initiatives at Medical Oncology Society in the Asia-Pacific Region アジア・パシフィック地域の各学会における腫瘍内科教育の取り組み	216
<b>CP5</b>	JSMO2024 Smoking Cessation Session JSMO2024 禁煙推進セッション	217

Meet the Experts

<b>ME9</b>	Are current follow up strategies for head and neck cancer still fit for purpose?	231
<b>ME10</b>	What is the next cutting-edge treatment for urothelial carcinoma ?	231
<b>ME11</b>	Essence of a Investigator, my message to young doctors in gynecologic oncology	232
<b>ME12</b>	Dermatological approach to patients with cancer- The value of a multidisciplinary approach	232
<b>ME13</b>	Antibody-drug conjugates: a pan-histologic revolution in the treatment of cancer	232

**Room 1 (1号館 2F センチュリーホール)**

8:40-11:20 Presidential Session 2

**PS2**

Gastrointestinal Cancer, Hematologic Malignancies, Genitourinary Cancer, Translational Research/ Clinical Pharmacology

消化器、血液、泌尿器、TR・臨床薬理



- Chairs : Hironobu Minami (Medical Oncology Hematology, Kobe University School of Medicine)  
Nicholas Turner (The University of Manchester)
- Discussants: Josep Taberero (Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO))  
Andrés Cervantes (INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain)  
Dai Maruyama (Cancer Institute Hospital, Japanese Foundation for Cancer Research)  
Kazutoshi Fujita (Department of Urology, Kindai University Faculty of Medicine)
- 司会 : 南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科)  
Nicholas Turner (The University of Manchester)
- ディスカッサント: Josep Taberero (Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO))  
Andrés Cervantes (INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain)  
丸山 大 (がん研究会有明病院 血液腫瘍科)  
藤田 和利 (近畿大学 泌尿器科)

**PS2-1 Landscape of Clonal Hematopoiesis by PBMC-Informed Liquid Biopsy in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-2**

Takao Fujisawa (Translational Research Support Office, National Cancer Center Hospital East / Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan)

藤澤 孝夫 (国立がん研究センター東病院医薬品開発推進部門TR支援室 / 国立がん研究センター東病院頭頸部内科)

**PS2-2 Analysis of ctDNA Changes in Locally Advanced Rectal Cancer that Underwent Neoadjuvant Treatment - GALAXY Trial-**Atsushi Hamabe (Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University / Department of Surgery, Surgical Oncology and Science, Sapporo Medical University)  
浜部 敦史 (大阪大学大学院医学系研究科 外科学講座 消化器外科学 / 札幌医科大学 消化器・総合、乳腺・内分泌外科学)**PS2-3 Epcoritamab SC in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL): EPCORE NHL-1 Dose Expansion**

Kim M Linton (The Christie NHS Foundation Trust and Manchester Cancer Research Centre)

**PS2-4 Characteristics of metastatic renal cell carcinoma via circulating tumor DNA: Nationwide SCRUM-Japan MONSTAR SCREEN study**Taigo Kato (Department of Urology, Osaka University Graduate School of Medicine)  
加藤 大悟 (大阪大学大学院医学系研究科 器官制御外科学泌尿器科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu)  
 Day 2 (Fri)  
 Day 3 (Sat)  
 On-demand  
 Room 1  
 Room 2  
 Room 3  
 Room 4  
 Room 5  
 Room 6  
 Room 7  
 Room 8  
 Room 9  
 Room 10  
 Room 11  
 Room 12  
 Room 13  
 Meet the Experts  
 Poster

15:00-17:00 Presidential Session 3

**PS3** new ADC (antibody drug conjugate)  
 新規抗体薬物複合体



Chairs : Hiroji Iwata (Aichi Cancer Center)

Sandra M. Swain (Georgetown University Medical Center, MedStar Health)

Discussants: Giuseppe Curigliano (European Institute of Oncology and University of Milano)

Kimio Yonesaka (Department of Medical Oncology, Kindai University)

司会 : 岩田 広治 (愛知県がんセンター 乳腺科)

Sandra M. Swain (Georgetown University Medical Center, MedStar Health)

ディスカッサント: Giuseppe Curigliano (European Institute of Oncology and University of Milano)

米阪 仁雄 (近畿大学医学部 腫瘍内科)

**PS3-1** **Dato-DXd vs chemotherapy for patients with inoperable/metastatic HR+/HER2- breast cancer: TROPION-Breast01 Asian subset**

Junji Tsurutani (Showa University Hospital, Tokyo, Japan)

**PS3-2** **Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2- metastatic breast cancer**

Hope S. Rugo (Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA)

**PS3-3** **Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors**

Toshihiko Doi (National Cancer Center Hospital East, Chiba, Japan)

土井 俊彦 (National Cancer Center Hospital East, Chiba, Japan)

## Room 2 (1号館 4F レセプションホール)

8:20-9:50 Presidential Symposium 4 / 会長企画シンポジウム 4

**PSY4** Fostering the Future of Clinical Oncology through Multidisciplinary Collaboration  
多学際領域との協働で奏でる臨床腫瘍学の未来



Chairs : Yasuhito Fujisaka (Medical Oncology, Osaka Medical and Pharmaceutical University)  
Yukari Tsubata (Department of Internal Medicine, Division of Medical Oncology & Respiratory  
Medicine, Shimane University Faculty of Medicine)  
司会 : 藤阪 保仁 (大阪医科薬科大学医学部 内科学講座腫瘍内科学)  
津端 由佳里 (島根大学医学部附属病院 呼吸器・化学療法内科)

### PSY4-1 Overture

Yukari Tsubata (Department of Internal Medicine, Division of Medical Oncology & Respiratory  
Medicine, Shimane University Faculty of Medicine)

#### オーバチュア

津端 由佳里 (島根大学医学部附属病院 呼吸器・化学療法内科)

### PSY4-2 Gender Medicine and Oncology

Anna D. Wagner (Department of Oncology, Division of Medical Oncology, Lausanne University  
Hospital and University of Lausanne)

### PSY4-3 Cardiology and Oncology, and Onco-Cardiology

Hiroshi Akazawa (Department of Cardiovascular Medicine, Graduate School of Medicine, The  
University of Tokyo)

#### 循環器学と腫瘍学と腫瘍循環器学

赤澤 宏 (東京大学大学院医学系研究科 循環器内科学)

### PSY4-4 Stroke Oncology

Hiroyuki Kawano (Department of Stroke and Cerebrovascular Medicine, Kyorin University, Japan)

#### 脳卒中学と腫瘍学

河野 浩之 (杏林大学医学部 脳卒中医学教室)

### PSY4-5 Rehabilitation Medicine and Oncology

Tetsuya Tsuji (Department of Rehabilitation Medicine, Keio University School of Medicine)

#### リハビリテーション医学と腫瘍学

辻 哲也 (慶應義塾大学医学部 リハビリテーション医学教室)

### PSY4-6 The Essence of Medical Oncology: Achieving Well-being of All Cancer Patients

Yasuhito Fujisaka (Medical Oncology, Osaka Medical and Pharmaceutical University)

#### 本質：がん関連学際領域との連携

藤阪 保仁 (大阪医科薬科大学医学部 内科学講座腫瘍内科学)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

9:50-11:20 Symposium 12 / シンポジウム 12

**SY12 Treatment Strategy of Cure for Patients with Thoracic Cancer**



Chairs : Hidetoshi Hayashi (Department of Medical Oncology, Kindai University)  
Yasushi Goto (National Cancer Center Hospital)

司会 : 林 秀敏 (近畿大学病院 腫瘍内科)  
後藤 悌 (国立がん研究センター中央病院)

**SY12-1 Up-to-date strategies for Prolonged Survival and Potential Cure in Locally Advanced Non-Small Cell Lung Cancer**

Kentaro Tanaka (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)

**局所進行非小細胞肺癌における生存期間の延長と治癒の可能性を目指す最新戦略**

田中 謙太郎 (九州大学大学院医学研究院 呼吸器内科学)

**SY12-2 Challenges for Long-Term Survival in Extended-Stage Small Cell Lung Cancer**

Kaname Nosaki (Department of Thoracic Oncology, National Cancer Center Hospital East)

**進展型小細胞肺癌治療における長期生存への挑戦**

野崎 要 (国立がん研究センター東病院 呼吸器内科)

**SY12-3 Treatment for oligometastatic NSCLC**

Hirotsugu Kenmotsu (Division of Thoracic Oncology, Shizuoka Cancer Center)

**オリゴメタスタシスを有する非小細胞肺癌の治療**

鉦持 広知 (静岡県立静岡がんセンター 呼吸器内科)

**SY12-4 Biomarkers for long-term efficacy of immune checkpoint inhibitors in metastatic NSCLC**

Hiroaki Kanemura (Department of Medical Oncology, Kindai University, Faculty of Medicine)

**切除不能NSCLCに対する免疫チェックポイント阻害薬の長期奏効バイオマーカー**

金村 宙昌 (近畿大学病院 腫瘍内科)

**SY12-5 Can Targeted Therapies Cure NSCLC with oncogenic driver mutation?**

Pasi Janne (Dana-Farber Cancer Institute)

15:00-16:30 Highlight of the Day 2

**HoD2**

Chairs : Tetsuji Takayama (Department of Gastroenterology and Oncology, Tokushima University  
Graduate School of Biomedical Sciences)

Seiji Yano (Kanazawa University)

司会 : 高山 哲治 (徳島大学大学院 医歯薬学研究部消化器内科学分野)  
矢野 聖二 (金沢大学医薬保健研究域医学系呼吸器内科学)

**HoD2-1 Hematology Oncology**

Eisei Kondo (Department of Hematology, Kawasaki Medical School)

**血液**

近藤 英生 (川崎医科大学 血液内科)

**HoD2-2 Urological Oncology**

Kouji Izumi (Department of Integrative Cancer Therapy and Urology, Kanazawa University)

**泌尿器**

泉 浩二 (金沢大学附属病院 医学系研究科集学的治療分野 (泌尿器科))

<b>HoD2-3</b>	<b>Gynecologic Oncology</b> Kan Yonemori (National Cancer Center Hospital) <b>婦人科</b> 米盛 勸 (国立がん研究センター中央病院 腫瘍内科)	Day 1 (Thu) <b>Day 2 (Fri)</b>
<b>HoD2-4</b>	<b>Palliative Care/Symptom Management</b> <b>緩和ケア支持療法</b> TBD	Day 3 (Sat)
<b>HoD2-5</b>	<b>Cross-sectional Program</b> Kenji Tamura (Department of Medical Oncology, Shimane University Hospital) <b>臓器横断プログラム</b> 田村 研治 (島根大学医学部附属病院 先端がん治療センター /腫瘍内科)	On-demand Room 1 <b>Room 2</b> Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Room 3 (1号館 4F 会議室 141+142)

8:20-9:50 Symposium 13 / シンポジウム 13

**SY13** UC medical oncology update: Know the true value of IO!  
尿路上皮癌薬物療法最前線: IOの真価を問う!



Chairs : Hiroshi Kitamura (Department of Urology, Faculty of Medicine, University of Toyama)  
Thomas Powles (Bart's Cancer Institute, Queen Mary University of London)  
司会 : 北村 寛 (富山大学学術研究部医学系 腎泌尿器科学講座)  
Thomas Powles (Bart's Cancer Institute, Queen Mary University of London)

**SY13-1 Emerging treatment for high risk non-muscle invasive bladder cancer: From BCG to immune checkpoint inhibitors and beyond**

Makito Miyake (Department of Urology, Nara Medical University, Nara, Japan)

ハイリスク筋層浸潤性膀胱癌に対する治療:  
BCG から免疫チェックポイント阻害剤へ、そしてその向こう

三宅 牧人 (奈良県立医科大学 泌尿器科)

**SY13-2 Perioperative immunotherapy for advanced urothelial carcinoma**

Atsunari Kawashima (Department of Urology, Graduate School of Medicine, Osaka University)

進行性尿路上皮癌に対する周術期免疫療法

河嶋 厚成 (大阪大学大学院医学系研究科 器官制御外科学講座 (泌尿器科学))

**SY13-3 Significant paradigm changes in systemic treatment for advanced urothelial carcinoma**

Aiko Maejima (Department of Medical Oncology/Urology, National Cancer Center Hospital)

進行性尿路上皮がん 薬物療法の大きなパラダイムチェンジを前に ー一次治療を中心に

前嶋 愛子 (国立がん研究センター中央病院 腫瘍内科/泌尿器・後腹膜腫瘍科)

**SY13-4 Pembrolizumab as second-line therapy for advanced urothelial carcinoma: Updated evidence of randomized trial and real-world data**

Takahiro Kojima (Department of Urology, Aichi Cancer Center Hospital)

進行性尿路上皮癌の2次治療における免疫チェックポイント阻害剤

小島 崇宏 (愛知県がんセンター病院 泌尿器科)

**SY13-5 Maintenance therapy in patients with metastatic urothelial carcinoma**

Chihiro Kondoh (Department of Medical Oncology, National Cancer Center Hospital East)

転移性尿路上皮癌の維持療法

近藤 千紘 (国立がん研究センター東病院 腫瘍内科)

**SY13-6 Future Prospects in UC Treatment**

Thomas Powles (Bart's Cancer Institute, Queen Mary University of London)



9:50-11:20 Presidential Symposium 5 / 会長企画シンポジウム 5

<b>PSY5</b>	What should Japan do about cancer care in a super-aging society? 超高齢社会のがん医療、日本はどうすべきか	<b>O</b>
Chairs :	Kazuo Tamura (NPO Clinical Hematology Oncology Treatment Study Group) Hiroyuki Umegaki (Department of Geriatrics Nagoya University Graduate School of Medicine)	
Discussants :	Madoka Yanagawa (Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine) Tetsuya Hamaguchi (Saitama Medical University International Medical Center/ JCOG Geriatric Study Committee) Kaori Yagasaki (Faculty of Nursing and Medical Care, Keio University) Tomonori Mizutani (Kyorin University Faculty of Medicine / Japan Geriatric Oncology Society) Ken Sugimoto (Department of General Geriatric Medicine, Kawasaki Medical School)	
司会 :	田村 和夫 (特定非営利活動法人 臨床血液・腫瘍研究会) 梅垣 宏行 (名古屋大学大学院医学系研究科 地域在宅医療学老年科学)	
ディスカッション :	濱口 哲弥 (埼玉医科大学国際医療センター /JCOG高齢者研究委員会) 矢ヶ崎 香 (慶應義塾大学 看護医療学部) 水谷 友紀 (杏林大学医学部 / 日本老年腫瘍研究会 (JGOS)) 杉本 研 (川崎医科大学 総合老年医学教室)	

**PSY5-KL 超高齢社会のがん医療に向けた行政の取り組み**

Jun Masuda (Ministry of Health, Labour and Welfare)  
増田 淳 (厚生労働省 健康・生活衛生局がん・疾病対策課)

15:00-16:40 Symposium 14 / シンポジウム 14

<b>SY14</b>	Precision medicine for colorectal cancer	<b>O E</b>
Chairs :	Toshiki Masuishi (Department of Clinical Oncology, Aichi Cancer Center Hospital) Josep Taberero (Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain)	
司会 :	舩石 俊樹 (愛知県がんセンター 薬物療法部) Josep Taberero (Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain)	
<b>SY14-1</b>	<b>Unveiling BRAF<sup>V600E</sup> Metastatic Colorectal Cancer as an entity of its own</b> Josep Taberero (Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain)	
<b>SY14-2</b>	<b>Target therapy for HER2-positive mCRC</b> Shota Fukuoka (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research) <b>HER2陽性大腸癌に対する治療開発</b> 福岡 聖大 (がん研究会有明病院 消化器化学療法科)	
<b>SY14-3</b>	<b>G12C KRAS mutant colorectal cancer, optimising the target</b> Timothy J Price (Department Medical Oncology, The Queen Elizabeth Hospital)	
<b>SY14-4</b>	<b>Immunotherapy for MSI-H locally advanced CRC</b> Taewon Kim (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)	

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

**SY14-5 Immunotherapy for metastatic coloractal cancer**

Akihito Kawazoe (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)

川添 彬人 (国立がん研究センター東病院 消化管内科)

## Room 4 (3号館 3F 国際会議室)

8:20-9:50 Symposium 15 / シンポジウム 15

**SY15** Secure the safety of anti-cancer drug administration - Device selection, Extravasation and Phlebitis  
抗がん剤を安全に投与する～デバイス選択、血管外漏出・静脈炎に取り組む～



Chairs : Koji Matsumoto (Division of Medical Oncology, Hyogo Cancer Center)  
Kaori Yagasaki (Faculty of Nursing and Medical Care, Keio University)  
司会 : 松本 光史 (兵庫県立がんセンター 腫瘍内科)  
矢ヶ崎 香 (慶應義塾大学 看護医療学部)

### SY15-1 Classification of Anticancer Drug Leakage Risk in Chemotherapy -Evidence and Its Exceptions-

Junya Sato (Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences)  
がん薬物療法における抗がん剤漏出リスクの分類について～エビデンスとその例外～  
佐藤 淳也 (湘南医療大学 薬学部)

### SY15-2 Safe administration of cancer chemotherapy; extravasation, phlebitis, device indication, and device selection

Koji Matsumoto (Division of Medical Oncology, Hyogo Cancer Center)  
抗がん剤を安全に投与する～デバイス選択、血管外漏出・静脈炎に取り組む～  
デバイス選択と管理  
松本 光史 (兵庫県立がんセンター 腫瘍内科)

### SY15-3 Prevention of Extravasation and Phlebitis

Naomi Fujikawa (Ishikawa Prefectural Central Hospital)  
がん薬物療法における血管外漏出や静脈炎の予防・早期発見に向けて  
藤川 直美 (石川県立中央病院 看護部)



### SY15-4 Treatment for extravasation - How should we do based on the evidence?-

Rumiko Okamoto (Department of Medical Oncology, Chemotherapy Center, Chiba Nishi General Hospital)  
血管外漏出時の治療 —エビデンスを踏まえどう対応していくべきか—  
岡元 るみ子 (千葉西総合病院 腫瘍内科外来化学療法センター)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

9:50-11:20 Symposium 16 / シンポジウム 16

**SY16** Next Stage of PPI (Patient and Public Involvement) in Japan- Involvement at the stage of regulatory approval and social implementation  
日本におけるPPI (患者・市民参画) のNext Stage ~当局承認から社会実装段階での関与  

Chairs : Kazuki Nozawa (Department of Center for Cancer Genomics and Advanced Therapeutics, Breast Oncology, Aichi Cancer Center Hospital)  
Naomi Sakurai (Cancer Survivors Recruiting Project / General Incorporated Association)

Panelists : Hiroshi Matsuzawa (Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association/ Astellas Pharma Inc.)  
Kaori Muto (The Institute of Medical Science, The University of Tokyo)  
Yasuhiro Fujiwara (Pharmaceuticals and Medical Devices Agency / National Cancer Center Hospital, Department of Medical Oncology)  
Shinsuke Amano (Japan Federation of Cancer Patient Groups)  
Yoshiaki Nakamura (International Research Promotion Office, National Cancer Center Hospital East)

司会 : 能澤 一樹 (愛知県がんセンター ゲノム医療センター がんゲノム医療室・乳腺科部)  
桜井 なおみ (一般社団法人CSRプロジェクト/全国がん患者団体連合会)

パネリスト : 松澤 寛 (日本製薬工業協会 医薬品評価委員会 臨床評価部会/アステラス製薬株式会社)  
武藤 香織 (東京大学医科学研究所)  
藤原 康弘 (独立行政法人 医薬品医療機器総合機構/国立がん研究センター中央病院 乳腺・腫瘍内科)  
天野 慎介 (全国がん患者団体連合会)  
中村 能章 (国立がん研究センター東病院 医薬品開発推進部門医薬品開発推進部)

**SY16-KL1 Patient and public involvement in medicine development, approval and reimbursement - the view from Europe**  
Neil Bertelsen (HTAi Patient & Citizen Involvement in HTA Group, PFMD)

**SY16-KL2 Advanced PPI initiative in the United States- the American Association for Cancer Research's Scientist ↔ Survivor Program**  
Jerry S. H. Lee (Ellison Institute of Technology)

15:00-16:30 ASCO/JSMO Joint Symposium / ASCO/JSMO 合同シンポジウム

**AJS** Drugging the Undruggable Targets  

Chairs : Lynn M. Schuchter (ASCO & University of Pennsylvania)  
Chikashi Ishioka (Tohoku University Graduate School of Medicine)

司会 : Lynn M. Schuchter (ASCO & University of Pennsylvania)  
石岡 千加史 (東北大学大学院医学系研究科)

**AJS-1 Targeting KRAS in Lung Cancer**  
Pasi Janne (Dana-Farber Cancer Institute)

**AJS-2 The TP53 Puzzle: Deciphering and Drugging a Tumor Suppressor**  
Lipika Goyal (Stanford School of Medicine)

**AJS-3 Drug development for undruggable target**  
Noboru Yamamoto (Department of Experimental Therapeutics, National Cancer Center Hospital)

**Undruggable target に対する抗がん剤開発**  
山本 昇 (国立がん研究センター中央病院 先端医療科)

**AJS-4 Targeting Wnt/  $\beta$  -catenin signaling: E7386, an orally active selective inhibitor of the interaction between  $\beta$  -catenin and CREB binding protein (CBP)**

Yusuke Adachi (Microenvironment Dynamics Domain, DHBL, Eisai Co., Ltd.)  
安達 雄亮 (エーザイ株式会社 DHBL Microenvironment Dynamics ドメイン)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Room 5 (4号館 3F 会議室 431+432)

8:20-10:20 Joint Symposium 5 (JSCN/JSMO) / 合同シンポジウム 5 (日本がん看護学会 / 日本臨床腫瘍学会)

**JS5** Cancer Genome Medicine-Harmony for patients  
がんゲノム医療-医師・看護師の協働でより良いがんゲノム医療を患者に-



Chairs : Kuniko Sunami (Department of Laboratory Medicine, National Cancer Center Hospital)  
Yuko Takeda (Faculty of Nursing and Medical Care, Keio University)  
司会 : 角南 久仁子 (国立がん研究センター中央病院 臨床検査科)  
武田 祐子 (慶應義塾大学 看護医療学部)

**JS5-1** Current status of precision oncology in daily practice

Kuniko Sunami (Department of Laboratory Medicine, National Cancer Center Hospital)

がんゲノム医療の実際

角南 久仁子 (国立がん研究センター中央病院 臨床検査科)

**JS5-2** The cross-sectional activities by Certified Nurse Specialist in Cancer Nursing in Cancer Genome Medicine

Ikuko Sugiyama (Department of Nursing, Tohoku University Hospital)

がんゲノム医療におけるがん看護専門看護師による横断的活動

杉山 育子 (東北大学病院 看護部緩和ケアセンター)

**JS5-3** Practices in Genomic and Genetic Nursing Committee and Participation of Generalist Nurses

Saki Hinoshita (Department of Nursing, Hyogo Cancer Center)

ゲノム・遺伝看護委員会の活動とジェネラリスト看護師の参画

日下 咲 (兵庫県立がんセンター 看護部)

**JS5-4** Collaboration between Medical Oncologists and Certified Nurse Specialist in Genetics Nurses: St. Luke's International Hospital's Attempt

Megumi Okawa (Nursing Department, St Luke's International Hospital)

腫瘍内科医師と遺伝看護専門看護師の協働—聖路加国際病院の試み—

大川 恵 (聖路加国際病院 看護部)

10:20-11:20 Mini Oral Session 22

**MO22** Patient Advocacy 1  
患者支援 1 (予防・栄養 教育)



Chairs : Kiyotaka Watanabe (Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University)  
Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University)  
司会 : 渡邊 清高 (帝京大学医学部附属病院 腫瘍内科)  
今村 知世 (昭和大学 先端がん治療研究所)

**MO22-1** Gender-Specific vs. Gender-Neutral Strategies for HPV-related Cancer Prevention: A Systematic Review and Meta-analysis

Nutthaporn Chandeying (Faculty of Medicine Vajira Hospital, Navamindradhiraj University)

**MO22-2** Unraveling the Best Defense: Meta-Analysis & Qualitative Comparative Analysis of HPV-Related Cancer Prevention Strategies

Therdpong Thongseiratch (Faculty of Medicine, Prince of Songkla University)

- MO22-3 Factors Associated with Dietary Habit Changes in Korean Stomach Cancer Survivors after Cancer Treatment**  
Junhee Park (Department of Family Medicine, Samsung Medical Center)
- MO22-4 Exploring Nutritional Guidance Needs and Influence Factors for Gastric Cancer Survivors in Community Health Center**  
Li Xie (Shanghai Jiao Tong University School of Medicine)
- MO22-5 Knowledge, Attitudes, and Practices of Oncology Fellows-in-Training on Oncofertility in Breast Cancer in The Young**  
Florge Francis A Sy (Division of Medical Oncology, Philippine General Hospital)
- MO22-6 Landscape of AJCC staging system: Limitations and improvements for communication with patients**  
Won Sup Yoon (Department of Radiation Oncology, Korea University Ansan Hospital)

15:00-17:00 Joint Symposium 6 (JSHG/JSMO) / 合同シンポジウム 6 (日本人類遺伝学会 / 日本臨床腫瘍学会)

- JS6 Cancer precision medicine and multi-gene panel testing**  
多遺伝子パネル検査 (MGPT) の実地臨床導入に関する課題 
- Chairs : Issei Imoto (Aichi Cancer Center Research Institute)  
Katsuya Tsuchihara (Exploratory Oncology Research and Clinical Trial Center, National Cancer Center)
- 司会 : 井本 逸勢 (愛知県がんセンター)  
土原 一哉 (国立がん研究センター先端医療開発センター)
- JS6-1 Cancer precision medicine and multi gene panel testing (MGPT) -Overview-**  
Akira Hirasawa (Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)  
**がんゲノム医療とMGPT-Overview-**  
平沢 晃 (岡山大学大学院医歯薬学総合研究科 臨床遺伝子医療学)
- JS6-2 BRANCH study: A clinical study for evaluating analytical validity and clinical utility of MGPT for hereditary tumors**  
Takeshi Kuwata (Department of Genetic Medicine and Services, National Cancer Center Hospital East)  
**MGPT 事業承認を目指した多施設共同臨床研究 (BRANCH study) の成果**  
桑田 健 (国立がん研究センター東病院 遺伝子診療部門)
- JS6-3 Guiding principle for the management of hereditary cancer syndromes using multi-gene panel testing (MGPT)**  
Reiko Yoshida (Saitama Cancer Center Department of Molecular Diagnosis and Cancer Prevention)  
**MGPTによる遺伝学的検査を用いた遺伝性腫瘍の診療・管理指針について**  
吉田 玲子 (埼玉県立がんセンター 腫瘍診断・予防科)
- JS6-4 Multi-gene Panel Testing (MGPT) for Hereditary Cancer and Genetic Counseling**  
Noriko Tanabe (Department of Clinical Genetics, Saitama Medical Center, Saitama Medical University / Department of Genetic Medicine and Services, National Cancer Center Hospital)  
**多遺伝子パネル検査 (MGPT) と遺伝カウンセリング**  
田辺 記子 (埼玉医科大学総合医療センター ゲノム診療科 / 国立がん研究センター中央病院 遺伝子診療部門)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

JS6-5

**Exploring Hereditary Tumors through Action Plan for Whole Genome Analysis 2022**

Makoto Hirata (Department of Genetic Medicine and Services, National Cancer Center Hospital)

**わが国の全ゲノム解析プロジェクトにおける遺伝性腫瘍解析**

平田 真 (国立がん研究センター 中央病院 遺伝子診療部門)



**Room 6 (1号館 3F 会議室 131+132)**

8:20-9:20 Mini Oral Session 23

**MO23** Palliative Care/Symptom Management 2  
緩和ケア・支持療法 2**E**

Chairs : Takaomi Kessoku (International University of Health and Welfare Narita Hospital)

Saiko Kurosawa (Ina Central Hospital)

司会 : 結束 貴臣 (国際医療福祉大学成田病院 緩和医療科)

黒澤 彩子 (伊那中央病院 腫瘍内科)

**MO23-1 Roles of Probiotics, Trimebutine Maleate, and Loperamide in Abemaciclib-Induced Diarrhea (WJOG11318B, MERMAID)**

Hitomi Sakai (Advanced Cancer Translational Research Institute, Showa University)

酒井 瞳 (昭和大学 先端がん治療研究所)

**MO23-2 Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: A single-arm trial**

Aya Nishizawa (Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital / Department of Dermatology, Cancer Institute Hospital, Japanese Foundation for Cancer Research,)

**レゴラフェニブによって生じる手足症候群 (HFSR) に対する塩化アルミニウムの発症予防効果の有効性：単群非ランダム化観察試験**

西澤 綾 (東京都立駒込病院 皮膚腫瘍科 / がん研有明病院 皮膚科)

**MO23-3 Efficacy and safety of gabapentinoids for chemotherapy-induced peripheral neuropathy: A retrospective study**

Yuya Yoshida (Department of Medical Oncology, Tohoku University Hospital, Miyagi, Japan)

**化学療法誘発性末梢神経障害に対するガバペンチノイドについての後方視的検討**

吉田 裕也 (東北大学病院 腫瘍内科)

**MO23-4 A feasibility study to evaluate clinical utility of stress data collection in cancer patients treated with chemotherapy**

Ayako Doi (Department of Clinical Oncology, St. Marianna University School of Medicine)

土井 綾子 (聖マリアンナ医科大学病院 臨床腫瘍学講座)

**MO23-5 A retrospective study of the management of distal lower extremity deep vein thrombosis in patients with cancer**

Hiroki Okumura (Department of Medical Oncology, Toranomon Hospital)

**担癌患者における遠位下肢深部静脈血栓症の管理についての後方視的検討**

奥村 浩基 (虎の門病院 臨床腫瘍科)

**MO23-6 Thromboembolism in advanced, recurrent, or metastatic solid tumors: 96-week final analysis of a prospective study**

Takahiro Tsuji (Department of Medical Oncology/Hematology, Kobe University Hospital)

辻 高寛 (神戸大学医学部附属病院 腫瘍血液内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

9:20-10:20 Mini Oral Session 24

**MO24** Cross-sectional Program 1 (Immunotherapy/Targeted therapy) **E**  
臓器横断プログラム 1 (免疫療法 / 分子標的療法)

Chairs : Kazuhiko Shibata (Division of Medical Oncology, Kouseiren Takaoka Hospital)  
Eiki Ichihara (Center for Clinical Oncology, Okayama University Hospital)

司会 : 柴田 和彦 (厚生連高岡病院 腫瘍内科)  
市原 英基 (岡山大学病院 呼吸器・アレルギー内科)

**MO24-1** **Outcomes of adjuvant therapy with anti-PD-1 antibody for mucosal melanoma**  
Mao Okumura (Department of Dermatologic Oncology, National Cancer Center Hospital)

粘膜悪性黒色腫に対する抗PD-1抗体による術後補助療法の効果  
奥村 真央 (国立がん研究センター中央病院 皮膚腫瘍科)

**MO24-2** **Real-world data on the efficacy of mycophenolate mofetil for hepatitis as immune-related adverse events of ICI**

Yukiko Igawa (Department of Thoracic Oncology, National Cancer Center Hospital)  
井川 由季子 (国立がん研究センター中央病院 呼吸器内科)

**MO24-3** **Human leukocyte antigen (HLA) type as a possible predictive marker for thyroid immune-related adverse event**

Yutaka Natori (Department of Medical Oncology, Fukushima Medical University)  
甲状腺irAE予測マーカーの可能性としてのヒト白血球抗原 (HLA) 型  
名取 稔 (福島県立医科大学 腫瘍内科学講座)

**MO24-4** **Current status of patients with tumor mutational burden-high in Niigata University Medical & Dental Hospital**

Mae Nakano (Division of Digestive and General Surgery, Niigata University)  
当院におけるTumor mutational burden-high 固形がんの現状  
中野 麻恵 (新潟大学 消化器・一般外科)

**MO24-5** **Efficacy of genotype-matched therapy in patients with locally advanced or metastatic solid tumors**

Tomohiro Kubo (Department of Medical Oncology, Sapporo Medical University School of Medicine)  
局所進行または転移性固形がんに対するgenotype-matched therapyの治療成績の検討  
久保 智洋 (札幌医科大学医学部 腫瘍内科学講座)

**MO24-6** **Feasibility of liquid-based CGP in solid tumor pts without sufficient tissue for NGS prior to the initial systemic Tx**

Takaaki Mizuno (Department of Experimental Therapeutics, National Cancer Center Hospital)  
水野 孝昭 (国立がん研究センター中央病院 先端医療科)

10:20-11:20 Mini Oral Session 25

**MO25** Cross-sectional Program 2 (New targeted therapy/Radiation therapy) **E**  
臓器横断プログラム 2 (新規薬物療法 / 放射線療法)

Chairs : Kenji Tamura (Department of Medical Oncology, Shimane University Hospital)  
Naoko Aragane (Dept of Internal Medicine, Faculty of Medicine, Saga Univ)

司会 : 田村 研治 (鳥根大学医学部附属病院 先端がん治療センター / 腫瘍内科)  
荒金 尚子 (佐賀大学 医学部内科)

**MO25-1** **Evaluation of HER2 Expression Across Various Solid Tumors in Vietnamese Patients: A Large-Scale Study**

Long Thanh Nguyen (Department of Medical Oncology No. 6, Vietnam National Cancer Hospital)

MO25-2	<b>Safety and pharmacokinetics of tusamitamab ravtansine dosing Q3W in Japanese patients with advanced solid tumors</b> Saori Mishima (National Cancer Center Hospital East) 三島 沙織 (National Cancer Center Hospital East)	Day 1 (Thu)
MO25-3	<b>Phase 1 study of tusamitamab ravtansine every 2 weeks with loading dose in Japanese patients with advanced solid tumors</b> Shigenori Kadowaki (Aichi Cancer Center Hospital) 門脇 重憲 (Aichi Cancer Center Hospital)	Day 2 (Fri)
MO25-4	<b>Potential Protective Effects of Trimetazidine Against New-Onset Cancer: A Territory-Wide Cardiac-Oncology Study</b> Yuen Ting Cheng (Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China)	Day 3 (Sat)
MO25-5	<b>Phase II study of 54 Gy accelerated hyperfractionated thoracic radiotherapy in limited-stage small-cell lung cancer</b> Miho Kono (Research Institute for Radiation Biology and Medicine) 限局型小細胞肺癌に対する加速過分割照射の線量増加第II相試験 河野 美保 (広島大学原爆放射線医科学研究所)	On-demand
MO25-6	<b>Hypofractionated Post-operative Radiation in Head and Neck Cancers (HNC): A Preliminary Account of Locoregional Control</b> Adrija Ghosh (Department of Radiation Oncology, NCI-AIIMS)	Room 1

15:00-16:30 Oral Session 9

<b>09</b>	<b>Rare Cancer</b> 希少がん・原発不明がん	<b>E</b>
Chairs :	Masashi Ando (Aichi Cancer Center Hospital, Department of Clinical Oncology) Tatsunori Shimoi (National Cancer Center Hospital Department of Medical Oncology)	Room 6
Discussant :	Kenji Tsuchihashi (Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital)	Room 7
司会 :	安藤 正志 (愛知県がんセンター 薬物療法部) 下井 辰徳 (国立がん研究センター中央病院 腫瘍内科)	Room 8
マイクサポート :	土橋 賢司 (九州大学病院 血液・腫瘍・心血管内科)	Room 9
<b>09-1</b> <b>Encore</b>	<b>Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial</b> Adnan Khattak (Hollywood Private Hospital and Edith Cowan University, Hollywood Specialist Centre)	Room 10
<b>09-2</b> <b>Encore</b>	<b>Genomic alterations in advanced gastrointestinal stromal tumors as revealed by comprehensive genomic profiling tests</b> Hiroyuki Fujii (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. / Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.) 藤井 博之 (国立がん研究センター中央病院 消化管内科 / 京都府立医科大学大学院医学研究科 呼吸器内科学教室)	Room 11
<b>09-3</b>	<b>Time to Surgery and Radioiodine for Patients with High-Risk Thyroid Carcinoma During the COVID-19 Pandemic in the U.S.</b> Luz Castellanos (Department of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center)	Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

**09-4** **An ML-based tool for predicting tissue of origin for cancer of unknown primary based on genomic and transcriptomic data**  
Zoia Antysheva (BostonGene, Corp.)

**09-5** **Efficacy of eribulin therapy in patients with advanced adenoid cystic carcinoma receiving platinum-based chemotherapy**  
Tomomi Sanomachi (Department of Medical Oncology, National Cancer Center Hospital)  
佐野町 友美 (国立がん研究センター中央病院 腫瘍内科総合レジデント)

**Room 7 (1号館 3F 会議室 133+134)**

8:20-9:20 Mini Oral Session 26

**MO26** Hematologic Malignancies 3 (Lymphoma 2)  
血液 3 (リンパ腫 2)

**E**

Chairs : Tsutomu Takahashi (Department of Hematology, Shimane University Hospital)  
Takahiro Yamauchi (University of Fukui)

司会 : 高橋 勉 (鳥根大学医学部附属病院 血液内科)  
山内 高弘 (福井大学医学部 血液・腫瘍内科)

**MO26-1** **Efficacy and Safety of Zanubrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Systematic Review**

Angelina Febrian Santoso (Faculty of Medicine, Pelita Harapan University)

**MO26-2** **Safety and Efficacy Ibrutinib in mantle-cell lymphoma: A Systematic Review of RCTs**

William Surya Atmaja (Faculty of Medicine, Pelita Harapan University)

**MO26-3** **Impact of introduce high-dose therapy on relapse and neurotoxicity free survival in patients with primary CNS lymphoma**

Naoki Uchida (Hematol., Toyohashi Municipal Hospital)

内田 直樹 (豊橋市民病院 血液・腫瘍内科)

**MO26-4** **A prospective analysis of MYC and BCL2 or BCL6 of patients with DLBCL**

Harunobu Tahara (Hematol., Toyohashi Municipal Hospital)

当院におけるびまん性大細胞型B細胞リンパ腫のMYCおよびBCL2またはBCL6の再構成について的前方視的検討

田原 玄寛 (豊橋市民病院 血液・腫瘍内科)

**MO26-5** **Prompt rituximab administration after brain biopsy potentially be associated with better prognosis in PCNSL patients**

Yasutaka Masuda (Department of Hematology and Oncology, The University of Tokyo Hospital)

増田 康隆 (東京大学医学部附属病院 血液・腫瘍内科)

**MO26-6** **Safety and Efficacy of Tis-cel Compared to Other CAR-T Cell Therapies as Treatment for R/R DLBCL: A Systematic Review**

Clarissa Ardalín Cendera (Faculty of Medicine, Pelita Harapan University)

9:25-10:15 Mini Oral Session 27

**MO27** Rare Cancer 3 (Central Nervous System Tumor)  
希少がん 3 (脳神経)

**E**

Chairs : Masamichi Takahashi (Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital)

Wataru Okamoto (Department of Clinical Oncology, Hiroshima University Hospital)

司会 : 高橋 雅道 (国立がん研究センター中央病院 脳脊髄腫瘍科)

岡本 渉 (広島大学病院 がん化学療法科)

**MO27-1** **Growth speed of meningiomas in older patients**

Hiroyuki Momota (Department of Neurosurgery, National Center for Geriatrics and Gerontology)

百田 洋之 (国立長寿医療研究センター 脳神経外科)

**MO27-2** **Intramedullary Spinal Cord Tumors (IMSCT) in paediatric population: a retrospective analysis of 45 cases**

Saurabh Gupta (Department of Neurosurgery, All India Institute of Medical Sciences, Delhi, India)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

- MO27-3** **Quantitative magnetic resonance imaging signal intensity in distinguishing between spinal meningiomas and schwannomas**  
Huyen Khanh Dang (Department of Radiology, Hanoi Medical University)
- MO27-4** **GFAP-positive Extracellular Vesicles and Autoantibodies are Abundant in the Sera of Malaysian Glioma Patients**  
Nadiyah Abu (UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia)
- MO27-5** **Concurrent Leiomyosarcoma and Diffuse Astrocytoma in a Li-Fraumeni Syndrome Patient: A Case Report**  
Noriaki Ito (Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University)  
**平滑筋肉腫とびまん性星細胞腫が併発したLi-Fraumeni症候群の一例**  
伊藤 徳明 (広島大学大学院 分子内科学)
- 
- 10:20-11:20 Mini Oral Session 28
- MO28** **Multidisciplinary Team Program 2**  
**多職種連携プログラム 2 (がん薬物療法)**
- Chairs : Junya Sato (Faculty of Pharmaceutical Science, Shonan University of Medical Science)  
Masashi Ando (Aichi Cancer Center Hospital, Department of Clinical Oncology)
- 司会 : 佐藤 淳也 (湘南医療大学 薬学部)  
安藤 正志 (愛知県がんセンター 薬物療法部)
- 
- MO28-1** **Analysis of tracing reports in outpatient cancer chemotherapy using text mining**  
Mai Takagi (Department of Hospital Pharmacy, National Cancer Center Hospital)  
**テキストマイニングを用いた外来がん薬物療法におけるトレーシングレポートの解析**  
高木 麻衣 (国立がん研究センター中央病院 薬剤部)
- 
- MO28-2** **Results of a Cy/5-FU Exposure Survey in an Outpatient Treatment Center -Including changes in exposure countermeasures-**  
Yukie Tomita (Division of Nursing, Anjo Kosei Hospital)  
**通院治療センターにおけるシクロフォスファミド・フルオロウラシルの曝露調査の結果～曝露対策の推移を含めて～**  
富田 幸枝 (安城更生病院 看護部)
- 
- MO28-3** **Development of the e-learning system with hands-on seminar for understanding hazardous drug exposure countermeasures**  
Kenjiro Aogi (Division of Clinical Research Promotion, NHO Shikoku Cancer Center)  
**職業性抗がん薬曝露の理解と対策推進のためのe-ラーニングシステム及び実地演習の開発**  
青儀 健二郎 (NHO四国がんセンター 臨床研究推進部)
- 
- MO28-4** **Survey of irAE occurrence and analysis of treatment progress through “irAE Team Rounds”**  
Nodoka Minami (Department of Pharmacy, Hyogo Cancer Center)  
**「irAEチームラウンド」によるirAE発生状況の調査および治療経過の分析**  
南 のどか (兵庫県立がんセンター 薬剤部)
- 
- MO28-5** **Outcomes of immune-related liver injury managed by hepatologists in a multidisciplinary toxicity team**  
Takanori Ito (Department of Gastroenterology and Hepatology, Nagoya University Hospital)  
伊藤 隆徳 (名古屋大学医学部附属病院 消化器内科)

**MO28-6 Current Status and Issues of "imNET" Activities of the Immune-Related Adverse Events Management Team in Kindai Hospital**

Takayuki Takahama (Department of Medical Oncology, Faculty of Medicine, Kindai University)

**近畿大学病院免疫関連有害事象対策チーム imNET 活動の現状と課題**

高濱 隆幸 (近畿大学医学部 腫瘍内科)

15:00-16:30 Oral Session 10

**O10 Patient Advocacy  
患者支援**

Chairs : Jiichiro Sasaki (Division of Clinical Oncology, Department of Comprehensive Medicine, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine)  
Haruru Kotani (Aichi Cancer Center Hospital, Breast Oncology Department)

Discussant : Satoshi Ikeda (Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center)

司会 : 佐々木 治一郎 (北里大学 医学部附属新世紀医療開発センター横断的医療領域開発部門臨床腫瘍学)  
小谷 はるる (愛知県がんセンター 乳腺科部)

ディスカッサント: 池田 慧 (神奈川県立循環器呼吸器病センター 呼吸器内科)

**O10-1 A Single Centre Experience on Adolescent and Young Adult Oncology (AYAO) Patient Perspectives on Fertility Preservation**

Zheng Xuan Ong (Department of Medical Oncology, National Cancer Centre Singapore)

**O10-2 Long-term health of breast cancer survivors: Analysis using pooled regional cancer registry data**

Miiko Sato (Medilocus, Department Gynecology, St. Luke International Hospital / Unit for Cancer Education, Kanagawa Cancer Center Research Institute)

**地域がん登録統合データを利用した、乳がんサバイバーの長期的健康に関する解析**

佐藤 美紀子 (聖路加国際病院 メディロウカス女性診療科 / 神奈川県立がんセンターがん教育ユニット)

**O10-3 Characteristics and support of cancer patients receiving financial counseling at a Cancer Counseling and Support Center**

Yuka Kawasaki (General Incorporated Association Cancer Life Advisor Association / Department of Medical Statistics, Research & Development Center Osaka Medical and Pharmaceutical University)

**がん相談支援センターでの経済面の相談におけるがん患者の特徴と支援：記述的研究**

川崎 由華 (一般社団法人がんライフアドバイザー協会 / 大阪医科薬科大学医学研究支援センター医療統計室)

**O10-4 Current Status and Future of Patient and Public Involvement in Pancreatic Cancer Clinical Practice Guidelines Revision**

Yasunari Sakamoto (Department of Gastroenterology and Hepatology, International University of Health and Welfare Atami Hospital / Japan Council for Quality Health Care)

**膵癌診療ガイドライン作成における患者・市民参画の現状と今後～医療者と患者・市民の融合～**

坂本 康成 (国際医療福祉大学熱海病院 消化器内科 / 日本医療機能評価機構 EBM医療情報部 (Minds))

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Room 8 (2号館 3F 会議室 234)

8:20-10:00 Symposium 17 / シンポジウム 17

**SY17** Let's understand clinical trial results more deeper: Discussion with statistical and economical experts  
臨床試験結果の深掘り：生物統計と医療経済の専門家を交えて

Chairs : Taro Shibata (National Cancer Center)  
Hideo Kunitoh (Japanese Red Cross Medical Center)  
司会 : 柴田 大朗 (国立がん研究センター)  
國頭 英夫 (日本赤十字社医療センター)

**SY17-1 Interpretation of clinical trials with different evaluations: Gynecologic cancer**  
Kosei Hasegawa (Department of Gynecologic Oncology, Saitama Medical University International Medical Center)

評価の割れた臨床試験の解釈：婦人科がんの場合  
長谷川 幸清 (埼玉医科大学国際医療センター 婦人科腫瘍科)

**SY17-2 肺がんに対する周術期臨床試験の統計・医療経済に関する課題**  
Masahiro Tsuboi (National Cancer Center Hospital East)  
坪井 正博 (国立がん研究センター東病院)

**SY17-3 A statistical interpretation of controversial clinical trial results**  
Shogo Nomura (Graduate School of Medicine, The University of Tokyo)

評価の割れた試験結果の解釈：生物統計家の立場から  
野村 尚吾 (東京大学大学院医学系研究科)

**SY17-4 医療経済の専門家による吟味**  
Ataru Igarashi (Yokohama City University, School of Medicine)  
五十嵐 中 (横浜市立大学医学群 データサイエンス研究科)

10:20-11:20 Committee Program 3 / 委員会企画 3 (教育企画部会 JSMO 大学)


**CP3** Is Oncology Not Popular? Discussing the reality of medical school education [JSMO University]  
腫瘍学は人気がないのか？医学部教育の実態に迫る [JSMO University]

Chairs : Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine)  
Hironaga Satake (Department of Medical Oncology, Kochi Medical School)  
Discussants: Hiroo Imai (Tohoku University Hospital)  
Makiko Ono (Department of Medical Oncology, Cancer Institute Hospital of JFCR)  
司会 : 砂川 優 (聖マリアンナ医科大学 臨床腫瘍学講座)  
佐竹 悠良 (高知大学医学部 腫瘍内科学講座)  
マイカサホト: 今井 源 (東北大学病院)  
小野 麻紀子 (がん研有明病院)

**CP3-KL1 JSMO University: Initiatives aimed at the development of oncology education in Japan**  
Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine)  
**JSMO University：本邦の腫瘍学教育の発展を目指した取り組み**  
砂川 優 (聖マリアンナ医科大学 臨床腫瘍学講座)

**CP3-KL2 Current Status of National Examination Education and Its Application to Oncology Education**  
Masahide Shiozawa (Hyogo Medical University)  
**国家試験教育の現状と腫瘍学教育への応用**  
塩澤 昌英 (兵庫医科大学)



<b>SY18</b>	Current status of head and neck cancer treatment aiming at personalized medicine and the future of new technology development 個別化医療を目指す頭頸部がん診療の現状と新規技術開発のゆくえ	
Chairs : Tomoya Yokota (Division of Gastrointestinal Oncology, Shizuoka Cancer Center) Bhumsuk Keam (Department of Internal Medicine, Seoul National University Hospital) 司会 : 横田 知哉 (静岡県立静岡がんセンター 消化器内科) Bhumsuk Keam (Department of Internal Medicine, Seoul National University Hospital)		
<b>SY18-1</b>	<b>Latest Overseas Trends Toward Personalized Medicine</b> Amanda Psyrrri (National Kapodistrian University of Athens, Greece)	
<b>SY18-2</b>	<b>The Current Status of Comprehensive Genomic Profile Testing in Head and Neck Cancer</b> Yoshinori Imamura (Medical Oncology/Hematology, Kobe University Hospital) <b>頭頸部がんにおける包括的ゲノムプロファイリング検査の現状</b> 今村 善宣 (神戸大学医学部附属病院 腫瘍・血液内科)	
<b>SY18-3</b>	<b>Current status and future perspectives of ctDNA in head and neck cancer</b> Tomohiro Enokida (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East) <b>頭頸部がんにおける ctDNA の現状と期待される展開</b> 榎田 智弘 (国立がん研究センター東病院 頭頸部内科)	
<b>SY18-4</b>	<b>Perspectives for Clinical Implementation of Multi-Omics Analysis in Precision Oncology</b> Takao Fujisawa (Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan) <b>Precision Oncology におけるマルチオミックス解析の臨床実装の展望</b> 藤澤 孝夫 (国立がん研究センター東病院医薬品開発推進部門トランスレーショナルリサーチ支援室)	

Room 9 (2号館 3F 会議室 232+233)

8:20-9:50 Committee Program 4 / 委員会企画 4 (教育企画部会)

**CP4** Oncology Education Initiatives at Medical Oncology Society in the Asia-Pacific Region  
アジア・パシフィック地域の各学会における腫瘍内科教育の取り組み



Chairs : Ichiro Kinoshita (Division of Clinical Cancer Genomics, Hokkaido University Hospital)  
Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)  
司会 : 木下 一郎 (北海道大学病院 がん遺伝子診断部)  
堀之内 秀仁 (国立がん研究センター中央病院 呼吸器内科)

**CP4-1** Oncology Education Initiatives at Medical Oncology Society in the Asia-Pacific Region  
- Medical Oncology Group of Australia

Melissa A Eastgate (Medical Oncology Group of Australia)

**CP4-2** Development of Oncology Fellowship between KSMO and KCSG in Korea: Current  
Status of Oncology Education and Framework for Future Oncology of KSMO

Yeon Hee Park (Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan  
University School of Medicine)

**CP4-3** Oncology Education Initiatives by Singapore Society of Oncology (SSO)

Eileen Yi Ling Poon (National Cancer Centre Singapore)

**CP4-4** Oncology Education Initiatives at Taiwan Oncology Society (TOS)

Chiun Hsu (Department of Medical Oncology, National Taiwan University Cancer Center, Taiwan  
/ Graduate Institute of Oncology, College of Medicine, National Taiwan University / Department  
of Oncology, National Taiwan University Hospital)

**CP4-5** Educational initiative at Japanese Society of Medical Oncology (JSMO): 2024 update

Ichiro Kinoshita (Division of Clinical Cancer Genomics, Hokkaido University Hospital)

**JSMOにおける腫瘍内科教育の取り組み**

木下 一郎 (北海道大学病院 がん遺伝子診断部)

9:50-11:20 Asia-Pacific/JSMO Joint Symposium / Asia-Pacific/JSMO 合同シンポジウム

**APJS** Education for Oncologists



Chairs : Takako Nakajima (Department of Early Clinical Development, Kyoto University Graduate School  
of Medicine)  
Josep Taberner (Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO))  
司会 : 中島 貴子 (京都大学大学院医学研究科 早期医療開発学)  
Josep Taberner (Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO))

**APJS-1** Investigator Sponsored Trial: Opportunities and Challenges

Myung-Ju Ahn (Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan  
University School of Medicine, Seoul, Korea)

**APJS-2** Addressing Global Barriers in Manuscript Submission

Herbert H Loong (The Chinese University of Hong Kong)

**APJS-3** Education for oncologists, pulmonologists and physician scientists in Japan

Eiji Iwama (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu  
University)

**本邦における腫瘍内科医、呼吸器内科医、Physician scientistの育成**

岩間 映二 (九州大学病院 呼吸器科)

APJS-4 **JSMO-Rising Stars in Asia Workshop - Initiatives for cultivating young Asian leaders and international exchange**

Kazuki Sudo (National Cancer Center Hospital)  
須藤 一起 (国立がん研究センター中央病院 腫瘍内科)

15:00-16:35 Committee Program 5 / 委員会企画 5 (広報渉外委員会企画)

**CP5** JSMO2024 Smoking Cessation Session  
JSMO2024 禁煙推進セッション



Chairs : Manabu Muto (Kyoto University Graduate School of Medicine Department of Therapeutic Oncology)

Minoru Fukuda (Cancer Center, Nagasaki Prefecture Shimabara Hospital)

司会 : 武藤 学 (京都大学大学院医学研究科 腫瘍薬物治療学講座)  
福田 実 (長崎県島原病院 がん診療センター)

**CP5-1** **加熱式タバコのエアロゾル成分解析**

Yohei Inaba (Cancer Center, National Institute of Public Health)  
稲葉 洋平 (国立保健医療科学院)

**CP5-2** **Evidence of heated tobacco in oncology field**

Minoru Fukuda (Cancer Center, Nagasaki Prefecture Shimabara Hospital)

**がん領域における加熱式たばこのエビデンス**  
福田 実 (長崎県島原病院 がん診療センター)

**CP5-3** **Self-management support provided by interprofessional team - using smoking cessation support**

Chie Taniguchi (College of Nursing, Aichi Medical University)

**医療多職種が連携して行うセルフマネジメント支援 ~禁煙支援を例に~**  
谷口 千枝 (愛知医科大学 看護学部)

**CP5-4** **Promoting smoking cessation from the patient's perspective**

Kazuo Hasegawa (Lung Cancer Patient Network ONE STEP)

**患者の立場から考える禁煙推進 結心プロジェクト・がん教育を題材として**  
長谷川 一男 (肺がん患者の会ワンステップ)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Room 10 (2号館 2F 会議室 224)

8:20-9:50 Symposium 19 / シンポジウム 19

**SY19** Genomic medicine and novel therapeutic strategy in blood cancer  
血液がんゲノム医療と新規分子標的治療



Chairs : Yosuke Minami (National Cancer Center Hospital East, Department of Hematology)  
Jorge E Cortes (Georgia Cancer Center at Augusta University)  
司会 : 南陽介 (国立がん研究センター東病院 血液腫瘍科)  
Jorge E Cortes (Georgia Cancer Center at Augusta University)

**SY19-1** Clinical application of genome profiling test for hematological malignancies

Masashi Sanada (Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center)

造血器腫瘍パネル検査の臨床実装に向けて

眞田 昌 (国立病院機構名古屋医療センター 臨床研究センター高度診断研究部)

**SY19-2** Novel therapeutic strategies with FLT3 inhibitors in AML

Mark J Levis (Department of Oncology, Johns Hopkins University)

**SY19-3** The current and future role of BCL2 inhibition in AML

**Encore** Courtney D. DiNardo (Department of Leukemia, University of Texas MD Anderson Cancer Center)

**SY19-4** Genetic alterations and their clinical significance in mature lymphoid neoplasms

Keisuke Kataoka (Division of Hematology, Department of Medicine, Keio University School of Medicine)

成熟リンパ系腫瘍における遺伝子異常の位置付けと臨床的意義

片岡 圭亮 (慶應義塾大学医学部 血液内科)

**SY19-5** Utility of Circulating tumor DNA based MRD monitoring Following Allogeneic Transplantation in Adult Acute Lymphoblastic Leukemia

Kazuaki Yokoyama (Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan)

成人ALLにおける同種移植後の腫瘍由来循環DNAを用いたMRD評価の有用性

横山 和明 (東京大学医科学研究所附属病院 血液腫瘍内科)

9:50-11:20 Symposium 20 / シンポジウム 20

**SY20** Treatment development for rare cancers  
希少がんの希少フラクションとしての治療開発



Chairs : Noboru Yamamoto (National Cancer Center Hospital)  
Kazunori Honda (Department of Clinical Oncology)  
司会 : 山本 昇 (国立がん研究センター中央病院)  
本多 和典 (愛知県がんセンター 薬物療法部)

**SY20-1** Drug development for rare cancers; things we learned from MASTER KEY Project and others

Hitomi Okuma (International Research and Development Section, Department of International Clinical Development, National Cancer Center Hospital)

希少がん治療開発の現状- MASTER KEYプロジェクトなど-

大熊 ひとみ (国立がん研究センター中央病院 国際開発部門/臨床研究支援部門/腫瘍内科)

SY20-2 Encore	<b>Extensive analysis of 59 sarcoma-related fusion genes identified pazopanib as a potential inhibitor to <i>COL1A1- PDGFB</i> fusion gene</b>	Takeshi Hirose (Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University / Division of Cellular Signaling, National Cancer Center Research Institute)	<b>59種類の肉腫関連融合遺伝子に対する広範な機能評価</b>	廣瀬 毅 (九州大学病院 整形外科 / 国立がん研究センター研究所 細胞情報学分野)
SY20-3	<b>Use of decentralized clinical trial for developing treatments in rare cancer</b>	Hiroya Taniguchi (Department of Clinical Oncology, Aichi Cancer Center Hospital)	<b>希少がん・希少フラグションの治療開発における decentralized clinical trial の活用</b>	谷口 浩也 (愛知県がんセンター 薬物療法部)
SY20-4	<b><i>SMARCA4</i> altered malignancy and its treatment</b>	Kei Kunimasa (Department of Thoracic Oncology, Osaka International Cancer Institute)	<b><i>SMARCA4</i> 変異悪性腫瘍とその治療法</b>	國政 啓 (大阪国際がんセンター 呼吸器内科)
SY20-5	<b><i>MDM2</i> Amplified Tumor</b>	Takafumi Koyama (Department of Experimental Therapeutics, National Cancer Center Hospital)	<b><i>MDM2</i> 増幅腫瘍</b>	小山 隆文 (国立がん研究センター中央病院 先端医療科)
15:00-16:30 Symposium 21 / シンポジウム 21				
SY21	<b>Challenge and Perspective of treatment in the field of gynecologic oncology</b>		<b>O E</b>	
婦人科がん領域の薬物療法の展望				
Chairs : Aikou Okamoto (Department of Obstetrics and Gynecology, The Jikei University School of Medicine)				
Kosei Hasegawa (Department of Gynecologic Oncology, Saitama Medical University International Medical Center)				
司会 : 岡本 愛光 (東京慈恵会医科大学 産婦人科) 長谷川 幸清 (埼玉医科大学国際医療センター 婦人科腫瘍科)				
SY21-1	<b>Tumor immune microenvironment and immunotherapy in gynecologic cancer</b>		Shohei Koyama (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center, National Cancer Center)	
<b>婦人科がんの腫瘍免疫微小環境と免疫療法</b>				
小山 正平 (国立がん研究センター先端医療開発センター 免疫トランスレーショナルリサーチ分野)				
SY21-2	<b>Challenge and Perspective of treatment in the field of uterine cancer and malignancies</b>		Domenica Lorusso (Gynaecological Oncology Unit at Humanitas Hospital San Pio X, Milan, Italy/ Obstetrics and Gynaecology, Humanitas University, Rozzano (MI), Italy)	
SY21-3	<b>Chemotherapy for advanced cervical cancer: Current challenges and future perspectives</b>		Hiroyuki Fujiwara (Department of Obstetrics and Gynecology, Jichi Medical University)	
<b>進行子宮頸癌に対する化学療法の現状と今後の展望</b>				
藤原 寛行 (自治医科大学 産科婦人科学講座)				
SY21-4	<b>Perspectives on the Future Landscape for Treatment of Epithelial Ovarian Cancer</b>		Kathleen N. Moore (Stephenson Cancer Center)	

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

**Room 11 (2号館 2F 会議室 221)**

8:20-9:10 Mini Oral Session 29

**MO29 Breast Cancer 3 (QOL) 乳腺 3 (QOL) E**

Chairs : Yuichiro Kikawa (Department of Breast Surgery, Kansai Medical University Hospital)  
Atsuko Kitano (St Luke's International Hospital, Department of Medical Oncology)  
司会 : 木川 雄一郎 (関西医科大学附属病院 乳腺外科)  
北野 敦子 (聖路加国際病院 腫瘍内科)

**MO29-1 演題取下**

**MO29-2 Japanese translation of the Functional Assessment of Cancer Therapy-Breast+4 (FACT-B+4) following international guideline**  
Takaïro Tsukioki (Department of Breast and Endocrine Surgery, Okayama University Hospital)  
突沖 貴宏 (岡山大学病院 乳腺・内分泌外科)

**MO29-3 Health-related Quality of Life and Patient Satisfaction After Breast Conserving Surgery and Intraoperative Radiotherapy**  
Angeli Andrea S. Cocos-Alcantara (Breast Section, Department of Surgery, The Medical City)

**MO29-4 The Effect of CoronaVirus 2019 (COVID-19) Pandemic on Breast Cancer's Dagnosis, Staging and Treatment**  
Chan Teng Chong (Department of Radiotherapy and Oncology, National Cancer Institute)

**MO29-5 Corelation of COVID-19 Pandemic and Medical Seeking Behaviour in Breast Cancer Patients at Siloam Hospitals Lippo Vilage**  
Christina Valeria Sie (Pelita Harapan University)

9:10-10:10 Mini Oral Session 30

**MO30 Breast Cancer 4 (Basic/Transrational research) 乳腺 4 (基礎、TR) E**

Chairs : Satomi Watanabe (Department of Medical Oncology, Kindai University Faculty of Medicine)  
Akihiko Shimomura (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)  
司会 : 渡邊 諭美 (近畿大学医学部 内科学教室腫瘍内科部門)  
下村 昭彦 (国立国際医療研究センター病院 乳腺・腫瘍内科)

**MO30-1 Neutrophils Resist Ferroptosis and Promote Breast Cancer Metastasis through ACOD1-mediated Metabolic Reprograming**  
Xin Lu (University of Notre Dame / Indiana University Simon Comprehensive Cancer Center)

**MO30-2 Prognostic impact of AKAP8 expression in breast cancer patients**  
Nana Matsumoto (Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences)  
松本 奈々 (名古屋市立大学大学院医学系研究科 乳腺外科学分野)

**MO30-3 FOXA1 Somatic Mutations as Independent Poor Prognostic Factors in Breast Cancer**  
Makiko Mori (Breast Surgery, Nagoya City University Graduate School of Medical Sciences)  
**FOXA1 体細胞変異は乳癌における独立した予後不良因子である**  
森 万希子 (名古屋市立大学大学院医学研究科 乳腺外科学分野)

**MO30-4** **Aberrant circulating cell-free DNA expression of *ER*, *PR*, *HER2*, and *MKI67* in breast cancer patients**  
Montalee Theeraapisakkun (Department of Biochemistry, Phramongkutklo College of Medicine, Bangkok, Thailand)

**MO30-5** **Inhibition of E3 Ubiquitin Ligase- HUWE1, suppresses Triple Negative Breast Cancer by regulating glucose metabolism**  
Shruti Kahol (Department of Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India)

**MO30-6** **Hinokitiol-Mediated Suppression of Stemness Progression in Breast Cancer through CD44/Nanog/SOX2/OCT4 Pathway Regulation**  
Ko-Chieh Huang (School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University)

10:20-11:20 Mini Oral Session 31

**MO31** **Gastrointestinal Cancer 5 (Esophageal Cancer, Perioperative, Others)**  
消化器 5 (食道がん・周術期, その他)

**E**

Chairs : Takashi Kojima (National Cancer Center Hospital East)  
Kenro Hirata (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)  
司会 : 小島 隆嗣 (国立がん研究センター東病院 消化管内科)  
平田 賢郎 (慶應義塾大学病院 内科学教室 (消化器))

**MO31-1** **Safety and Efficacy of Preoperative FOLFOX in Cisplatin-ineligible Patients With Esophageal Squamous Cell Carcinoma**  
Amane Jubashi (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)  
重橋 周 (国立がん研究センター東病院 消化管内科)

**MO31-2** **The safety of neoadjuvant DCF therapy for locally advanced esophageal cancer at our hospital**  
Yumi Sakaguchi (Department of Medical Oncology, Osaka City General Hospital)  
坂口 結美 (大阪市立総合医療センター 腫瘍内科)

**MO31-3** **Efficacy of mucosal recurrence prevention by adjuvant radiotherapy after endoscopic resection for early esophagus cancer**  
Hirofumi Fukushima (Department of Gastroenterology, Juntendo University School of Medicine)  
**非治癒切除早期食道癌における放射線照射による局所粘膜再発予防の有効性**  
福嶋 浩文 (順天堂大学医学部附属順天堂医院 消化器内科)

**MO31-4** **Treatment Preference assessed by discrete choice experiments for Patients with Esophageal Cancer in Japan (PPEC study)**  
Yasuo Hamamoto (Keio Cancer Center, Keio University School of Medicine)  
浜本 康夫 (慶應義塾大学医学部 腫瘍センター)

**MO31-5** **Elafin in Esophageal Squamous Cell Carcinoma: A Study on 3D Imaging & Genomic Mechanisms as Prognostic Indicators**  
I-Chen Wu (Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital / Department of Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University / Center for Cancer Research, Kaohsiung Medical University)

**Encore**

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

**MO31-6 An analysis of the exome and transcriptome for mutational landscape of squamous cell carcinoma of the esophagus**  
Naveen Kumar (Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi)

15:00-16:00 Mini Oral Session 32

**MO32** Translational Research/ Clinical Pharmacology 2 (Comprehensive Genomic Profiling)  
TR・臨床薬理 2 (分子・遺伝子診断 (遺伝子パネル検査含)) **E**

Chairs : Masashi Kanai (Cancer Treatment Center, Kansai Medical University Hospital)  
Daisuke Sakai (Department of Medical Oncology, Osaka International Cancer Institute)

司会 : 金井 雅史 (関西医科大学附属病院 がんセンター)  
坂井 大介 (大阪国際がんセンター 腫瘍内科)

**MO32-1 Assessing the Impact of Comprehensive Genome Profiling in Clinical Practice: Single-Center Observational Study in Japan**  
Naotoshi Sugimoto (Department of Genetic Oncology, Osaka International Cancer Institute)  
杉本 直俊 (大阪国際がんセンター 遺伝子診療部)

**MO32-2 Comparison based on the CGP test results between the early and the late period for access to treatments**  
Masumi Yamazaki (Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan / Development of Advanced Cancer Therapy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan)

**CGP検査結果に基づく前期と後期の治療到達率の比較について**  
山崎 真澄 (がん研究会有明病院 ゲノム診療部 / がん研有明病院先進がん治療開発センター)

**MO32-3 Comprehensive genome profiling utilization for other than companion diagnosis: drug selection for soft-tissue sarcoma**  
Masachika Ikegami (Department of Musculoskeletal Oncology, Komagome Hospital)

**コンパニオン診断以外での包括的がんゲノムプロファイリングの活用：軟部肉腫の薬剤選択**  
池上 政周 (東京都立駒込病院 骨軟部腫瘍科)

**MO32-4 Utility of comprehensive genomic profiling among AYA cancer patients**  
Naomi Hayashi (Department of Genomic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research / Department of Clinical Genetic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research)

林 直美 (がん研究会有明病院 ゲノム診療部 / がん研究会有明病院 臨床遺伝医療部)

**MO32-5 Impact of patient travel costs on disparities in precision oncology clinical trials**  
Yuji Uehara (Department of Thoracic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center - Komagome Hospital / Department of Experimental Therapeutics, National Cancer Center Hospital)

**プレジジョン・オンコロジーにおいて、患者の交通費が遺伝子変異にマッチした治験の地域格差に与える影響**  
上原 悠治 (東京都立駒込病院 呼吸器内科 / 国立がんセンター中央病院 先端医療科)

**MO32-6 Incidental Germline Variants among Adults with Solid Cancers who Underwent Tumor Genomic Profiling in the Philippines**  
Paula Isabel G. Franco (Cancer Institute, St. Luke's Medical Center, Quezon City)



**MO33** Hepatobiliary/ Pancreatic Cancer 3 (Pancreatic Cancer 3 (Gallbladder and Biliary Tract Cancer 1)  
肝胆膵 3 (膵臓 3 (胆嚢・胆道 1))

E

Chairs : Susumu Hijioka (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)

Shuichi Mitsunaga (National Cancer Center)

司会 : 脇岡 範 (国立がん研究センター中央病院 肝胆膵内科)

光永 修一 (国立がん研究センター 先端医療開発センター)

**MO33-1** **The efficacy of stereotactic body radiation therapy for liver metastases in patients with advanced pancreatic cancer**

Hiroki Kishimoto (Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute)

岸本 弘基 (大阪国際がんセンター 肝胆膵内科)

**MO33-2** **Bone loss over time and risk of osteoporosis in advanced pancreatic cancer**

Tsuyoshi Takeda (Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research)

武田 剛志 (がん研究会有明病院 肝胆膵内科)

**MO33-3** **Outcomes of anticancer treatment for super-aged (more than 85years) patients with pancreatic cancer in our institute**

Takuo Yamai (Department of Gastroenterology and Hepatology, Osaka General Medical Center)

山井 琢陽 (大阪急性期・総合医療センター 消化器内科)

**MO33-4** **Prognostic Factors for GEM + nab-PTX Combination Therapy in Elderly Patients with Pancreatic Cancer**

Kazuki Watabe (Department of Gastroenterology, Chiba University)

渡部 主樹 (千葉大学 消化器内科)

**MO33-5** **Study of relationship between neutrophil gelatinase-associated lipocalin and benign pancreatic diseases in aged patients**

Pardeep Kumar (F H Medical College & Hospital)

**MO33-6** **Efficacy and safety of EUS-guided hepaticogastrostomy for malignant biliary obstruction in patients with ascites**

Iori Motoo (Third Department of Internal Medicine, University of Toyama)

元尾 伊織 (富山大学附属病院 第3内科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Room 12 (2号館 2F 会議室 222+223)

8:20-9:50 Oral Session 11

**O11** Lung Cancer/ Thoracic Cancer 2  
呼吸器 2

**E**

Chairs : Isamu Okamoto (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)

Tatsuya Yoshida (National Cancer Center Hospital, Department of Thoracic Oncology)

Discussants: Martin Reck (German Center of Lung Research)

Nobuaki Mamesaya (Division of Thoracic Oncology, Shizuoka Cancer Center)

司会 : 岡本 勇 (九州大学大学院医学研究院 呼吸器内科学分野)

吉田 達哉 (国立がん研究センター中央病院 呼吸器内科)

ディスカッサント: Martin Reck (German Center of Lung Research)

豆鞆 伸昭 (静岡県立静岡がんセンター 呼吸器内科)

**O11-1** **TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated NSCLC with actionable genomic alterations (AGAs)**

**Encore**

Satoru Kitazono (The Cancer Institute Hospital of JFCR, Tokyo, Japan)

北園 聡 (がん研究会有明病院 呼吸器内科)

**O11-2** **T-DXd in HER2-mutant (HER2m) metastatic NSCLC with and without brain metastases: pooled analyses from DESTINY-Lung01/02**

**Encore**

Yasushi Goto (National Cancer Center Hospital, Tokyo, Japan)

後藤 悌 (国立がん研究センター中央病院 呼吸器内科)

**O11-3** **Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results from EVOKE-02**

**Encore**

Byoung C Cho (Yonsei Cancer Center, Seoul, Republic of Korea)

**O11-4** **Nivolumab for malignant non-pleural mesothelioma (VIOLA): Japanese phase II investigator-initiated clinical trial**

Koji Mikami (Department of Respiratory Medicine and Hematology, Hyogo Medical University)

**胸膜以外原発悪性中皮腫に対するニボルマブの第2相医師主導治験: VIOLA**

三上 浩司 (兵庫医科大学 呼吸器血液内科)

**O11-5** **Tarlatamab for patients with pretreated small cell lung cancer: Primary analysis of the phase 2 DeLLphi-301 study**

**Encore**

Hiroki Izumi (Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan)

泉 大樹 (Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan)

<b>012</b>	<b>Palliative Care/Symptom Management</b> 緩和ケア・支持療法	<b>E</b>
Chairs :	Tomofumi Miura (Department of Palliative Medicine, National Cancer Center Hospital East) Yuko Tanabe (Toranomon Hospital)	
Discussants :	Takeshi Yoshida (Palliative Care Center and Department of Medical Oncology, Kindai University Hospital) Hiroto Ishiki (Department of Palliative Medicine, National Cancer Center Hospital)	
司会 :	三浦 智史 (国立がん研究センター東病院 緩和医療科) 田辺 裕子 (虎の門病院 臨床腫瘍科)	
ディスカッサント :	吉田 健史 (近畿大学病院がんセンター緩和ケアセンター・腫瘍内科兼務) 石木 寛人 (国立がん研究センター中央病院 緩和医療科)	

**012-1 Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer**

Naoya Hashimoto (Department of Pharmacy, Aichi Cancer Center Hospital)  
橋本 直弥 (愛知県がんセンター病院薬剤部)

**012-2 A Randomized Phase 2 Study Investigating Optimal Antiemetic Therapy for Patients with Gastric Cancer Treated with T-DXd**

Kazuhiro Nishikawa (Osaka Police Hospital)

**トラスツズマブ デルクステカン (T-DXd) 施行の切除不能再発胃癌患者に対する至適な制吐療法を検討する多施設共同ランダム化第2相試験**

西川 和宏 (大阪警察病院 がん診療センター)

**012-3 A multicenter prospective study of CIPN incidence and risk factors in cancer patients receiving oxaliplatin or taxanes**

Aoi Hino (Department of Internal Medicine, Chiba Medical Center, Chiba, Japan / Department of Respiriology, Graduate School of Medicine, Chiba University, Chiba, Japan)

**オキサリプラチンまたはタキサン系製剤による治療を開始したがん患者を対象にCIPN頻度およびリスク因子を検討した多施設共同前向き研究：MiroCIP Study**

日野 葵 (千葉メディカルセンター 内科 / 千葉大学大学院医学研究院 呼吸器内科学)

**012-4 Real-world data on efficacy of infliximab for immune-related colitis during ICI treatment**

Yuri Yoshinami (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

**免疫チェックポイント阻害剤治療中の免疫関連大腸炎に対するインフリキシマブの実臨床データ**

善浪 佑理 (国立がん研究センター中央病院 消化管内科)

**012-5 Comparison of psychological burden between hematologists and palliative care physicians: A nationwide survey**

Yukako Hattori (Department of Hematology/Oncology, Yamato Municipal Hospital / Department of Palliative Medicine, National Cancer Center Hospital East)

服部 友歌子 (大和市立病院 血液・腫瘍内科 / 国立がん研究センター東病院 緩和医療科)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

15:00-16:00 Mini Oral Session 34

**MO34** Lung Cancer/ Thoracic Cancer 4 (Non-Small Cell Lung Cancer-Chemotherapy・TKI)  
呼吸器 4 (非小細胞肺癌・化学療法・TKI) E

Chairs : Takashi Seto (NHO Kyushu Cancer Center Thoracic Oncology)  
Yukari Tsubata (Shimane University Hospital)  
司会 : 瀬戸 貴司 (九州がんセンター 呼吸器腫瘍科)  
津端 由佳里 (鳥根大学医学部附属病院 呼吸器・化学療法内科)

**MO34-1** **Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC After EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01**

**Encore**

Yasushi Goto (National Cancer Center Hospital)  
後藤 悌 (National Cancer Center Hospital)

**MO34-2** **Final Phase 1b Study Results of Telisotuzumab Vedotin and Osimertinib in Asian vs Non-Asian Patients With Advanced NSCLC**

Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)  
堀之内 秀仁 (国立がん研究センター中央病院 呼吸器内科)

**MO34-3** **The efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202**

Yosuke Kawashima (Department of Pulmonary Medicine, Sendai Kousei Hospital)  
川嶋 庸介 (仙台厚生病院 呼吸器内科)

**MO34-4** **Chemotherapy for advanced pulmonary sarcomatoid carcinoma: A population-based propensity score matching study**

**Encore**

Feng Wang (Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute)

**MO34-5** **The improvements in the prognosis of Stage IV non-small cell lung cancer over two decades from 2001**

Hironori Satoh (Department of Thoracic Oncology, National Cancer Center Hospital / Hoshi University School of Pharmacy and Pharmaceutical Sciences)

**IV期肺非小細胞がんの過去20年間の著明な生存期間の改善**

佐藤 大希 (国立がん研究センター中央病院 呼吸器内科 / 星薬科大学 大学院)

**MO34-6** **Real-World Data on the efficacy of Alectinib in ALK rearranged NSCLC patients**

Yukiko Hibino (Department of Thoracic Oncology, National Cancer Center Hospital)  
日比野 幸子 (国立がん研究センター中央病院 呼吸器内科)

16:00-17:00 Mini Oral Session 35

**MO35** Lung Cancer/ Thoracic Cancer 5 (Non-Small Cell Lung Cancer-Locally Advanced・Perioperative Treatment)  
呼吸器 5 (非小細胞肺癌・局所進行・周術期) E

Chairs : Seiji Niho (Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University)  
Yuichi Tambo (Respiratory Medicine, Kanazawa University Hospital)  
司会 : 仁保 誠治 (獨協医科大学 呼吸器・アレルギー内科)  
丹保 裕一 (金沢大学附属病院 呼吸器内科)

**MO35-1** **Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: a retrospective study (HOT2101)**

Jun Sugisaka (Department of Pulmonary Medicine, Sendai Kousei Hospital)  
杉坂 淳 (仙台厚生病院 呼吸器内科)

- MO35-2** **Real-world data of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected NSCLC (NEJ056)**  
**Encore** Teppei Yamaguchi (Department of Thoracic Oncology, Aichi Cancer Center Hospital)  
 山口 哲平 (愛知県がんセンター 呼吸器内科)
- MO35-3** **A phase II study of weekly carboplatin and concurrent radiotherapy for locally advanced NSCLC in elderly patients**  
 Taishi Harada (Department of Respiratory Medicine, Japan Community Healthcare Organization Kyushu Hospital)  
 原田 大志 (九州病院 内科 (呼吸器))
- MO35-4** **A prospective biomarker study of durvalumab after dCCRT in patients with unresectable stage III NSCLC (WJOG11518L)**  
**Encore** Nobuaki Mamesaya (Division of Thoracic Oncology, Shizuoka Cancer Center)  
 切除不能Ⅲ期非小細胞肺癌における根治的化学放射線療法後durvalumabの前向き biomarker 試験 (WJOG11518L)  
 豆鞆 伸昭 (静岡県立静岡がんセンター 呼吸器内科)
- MO35-5** **Monitoring of peripheral PD-1-positive lymphocytes in patients with non-small-cell lung cancer**  
 Koji Teramoto (Department of Medical Oncology, Shiga University of Medical Science / Cancer for Advanced Medicine Against Cancer, Shiga University of Medical Science)  
 寺本 晃治 (滋賀医科大学 臨床腫瘍学講座 (腫瘍内科) / 滋賀医科大学 先端がん研究センター)
- MO35-6** **The Japan Lung Society Integrated Clinical Trial Database (JIDB) and Data Sharing: Pioneering for New Possibilities**  
 Yuichi Ozawa (Department of Respiratory Medicine, Hamamatsu Medical Center / Internal Medicine III, Wakayama Medical University)  
**日本肺癌学会臨床試験統合データベース (JIDB) の構築と研究公募**  
 小澤 雄一 (浜松医療センター 呼吸器内科 / 和歌山県立医科大学 呼吸器内科・腫瘍内科)

Day 1 (Thu)  
 Day 2 (Fri)  
 Day 3 (Sat)  
 On-demand  
 Room 1  
 Room 2  
 Room 3  
 Room 4  
 Room 5  
 Room 6  
 Room 7  
 Room 8  
 Room 9  
 Room 10  
 Room 11  
 Room 12  
 Room 13  
 Meet the Experts  
 Poster

**Room 13 (2号館 1F 展示室 211)**

8:20-9:50 Oral Session 13

**O13 Gynecologic Cancer 婦人科** **E**

Chairs : Jing Li (Sun Yat-sen Memorial Hospital, Sun Yat-sen University)  
 Jae Weon Kim (Seoul National University (Hospital))  
 Discussants: Jack Chan (Duke-NUS Medical School / National Cancer Centre Singapore)  
 Jing Li (Sun Yat-sen Memorial Hospital, Sun Yat-sen University)  
 Jae Weon Kim (Seoul National University (Hospital))  
 司会 : Jing Li (Sun Yat-sen Memorial Hospital, Sun Yat-sen University)  
 Jae Weon Kim (Seoul National University (Hospital))  
 ティスカサホ: Jack Chan (Duke-NUS Medical School / National Cancer Centre Singapore)  
 Jing Li (Sun Yat-sen Memorial Hospital, Sun Yat-sen University)  
 Jae Weon Kim (Seoul National University (Hospital))

**013-1 PD-L1 status and survival outcomes of triplet maintenance in *BRC*Awildtype recurrent ovarian cancer: OPEB-01/APGOT-OV4**  
 Jung-Yun Lee (Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea)

**013-2 Raludotatug deruxtecan (R-DXd; DS-6000) in Japanese patients with ovarian cancer: subgroup analysis of a phase 1 study**  
 Kazuki Sudo (National Cancer Center Hospital, Tokyo, Japan)  
 須藤 一起 (National Cancer Center Hospital, Tokyo, Japan)

**013-3 Predicting therapeutic response to PARP inhibitors in high-grade serous ovarian cancer: A Comprehensive proteomics study**  
 Se Ik Kim (Department of Obsetetrics and Gynecology, Seoul National University College of Medicine)


**013-4 innovaTV 301: A Phase 3 Study of Tisotumab Vedotin vs Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer**  
 Kan Yonemori (National Cancer Center Hospital)  
 米盛 勸 (National Cancer Center Hospital)

**013-5 Dostarlimab for primary advanced or recurrent endometrial cancer: Blinded independent central review – RUBY trial**  
 Mansoor R. Mirza (Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, and Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen Denmark)

<b>O14</b>	<b>Cross-sectional Program</b> <b>臓器横断プログラム</b>	<b>E</b>
<p>Chairs : Chihiro Kondoh (Department of Medical Oncology, National Cancer Center Hospital East)  Akitaka Makiyama (Cancer Center, Gifu University Hospital)</p> <p>Discussant : Shingo Yano (The Jikei University School of Medicine)</p> <p>司会 : 近藤 千紘 (国立がん研究センター東病院 腫瘍内科)  牧山 明資 (岐阜大学医学部附属病院 がんセンター)</p> <p>マイクホスト: 矢野 真吾 (東京慈恵会医科大学附属病院 血液・腫瘍内科)</p>		
<b>O14-1</b>	<b>A first-in-human study of ABBV-400, a c-Met-targeting antibody-drug conjugate, in patients with advanced solid tumors</b>	
<b>Encore</b>	<p>Yasutoshi Kuboki (Department of Experimental Therapeutics, National Cancer Center Hospital East)</p> <p><b>進行固形癌患者を対象としたc-Metを標的とする抗体薬物複合体であるABBV-400のヒト初回投与試験</b></p> <p>久保木 恭利 (国立がん研究センター東病院 先端医療科)</p>	
<b>O14-2</b>	<b>Updated Tumor Agnostic Efficacy of Selpercatinib in Patients with <i>RET</i> Fusion-Positive Solid Tumors: LIBRETTO-001</b>	
<p>Yuichiro Ohe (National Cancer Center)  大江 裕一郎 (National Cancer Center)</p>		
<b>O14-3</b>	<b>Efficacy of Platinum-Based Chemotherapy in BRCA-mut Advanced Solid Tumors: Analysis Using the C-CAT Database</b>	
<p>Naoya Ishibashi (Department of Precision Cancer Medicine, Tokyo Medical and Dental University Hospital / Department of Gastrointestinal Surgery, Tokyo Medical and Dental University)  石橋 直弥 (東京医科歯科大学病院 がんゲノム診療科 / 東京医科歯科大学 消化管外科学分野)</p>		
<b>O14-4</b>	<b>Prevalence and clinical characteristics of pathogenic germline variants based on real-world cancer genome profiling</b>	
<p>Tomoyuki Satake (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East / Department of Experimental Therapeutics, National Cancer Center Hospital)  佐竹 智行 (国立がん研究センター東病院 肝胆膵内科 / 国立がん研究センター中央病院 先端医療科)</p>		
<b>O14-5</b>	<b>Anticoagulation for distal deep venous thrombosis in cancer patients; a post-hoc analysis from PROVE-emboli study</b>	
<p>Taku Nose (Department of Medical Oncology/Hematology, Kobe University Hospital)  能勢 拓 (神戸大学医学部附属病院 腫瘍・血液内科)</p>		

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

15:00-16:30 Symposium 22 / シンポジウム 22

**SY22** How far can we go? Palliative and end-of-life care at home  
 こもまでできる！どこまでできる？在宅緩和・終末期医療を考える 

Chairs : Masakazu Abe (Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine)  
 Keita Tagami (Department of Palliative Home Care, Yamato Home Care Clinic Tome / Department of Palliative Care, Tokunoshuima Tokushukai Hospital / Yoshiki Home Care Clinic/ KISA2-Tai / Department of Palliative Medicine, Tohoku University Graduate School of Medicine)  
 司会 : 安部 正和 (浜松医科大学 産婦人科)  
 田上 恵太 (やまと在宅診療所登米 在宅緩和ケア / 徳之島徳洲会病院 緩和ケアチーム / よしき往診クリニック/KISA2隊 / 東北大学大学院医学系研究科 緩和医療学分野)

**SY22-1** **How to support cancer patients in a home care setting from the perspective of a hospital**  
 Yoshihisa Matsumoto (Department of Palliative Therapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research)

**いかに患者の在宅療養をサポートするか ~病院側にできる在宅療養のサポート~**  
 松本 禎久 (がん研究会有明病院 緩和治療科)

**SY22-2** **Breaking the limits of Home Palliative Care, As a position of home care doctor**  
 Kazuhiko Fukumoto (Iwata Home Care Clinic)

**こもまでできる在宅緩和ケア ~医師の立場として**  
 福本 和彦 (磐田在宅医療クリニック)

**SY22-3** **Breaking the limits of Home Palliative Care, As a position of nurse**  
 Yasuyo Oishi (Iwata Home Care Clinic)

**こもまでできる在宅緩和ケア ~看護師の立場として**  
 大石 恭代 (磐田在宅医療クリニック)

**SY22-4** **Embracing Community: Enhancing Well-Being with Palliative Care Services Throughout Life**

Keita Tagami (Department of Palliative Home Care, Yamato Home Care Clinic Tome / Department of Palliative Care, Tokunoshuima Tokushukai Hospital / Yoshiki Home Care Clinic/ KISA2-Tai / Department of Palliative Medicine, Tohoku University Graduate School of Medicine)

**地域を愛する気持ち×地域の緩和ケアシステム∞！**  
**住み慣れた地域で最期までよく生きるためのハウツー**

田上 恵太 (やまと在宅診療所登米 在宅緩和ケア / 徳之島徳洲会病院 緩和ケアチーム / よしき往診クリニック/KISA2隊 / 東北大学大学院医学系研究科 緩和医療学分野)

**SY22-5** **Living well on the remote island until the end: Home-based palliative care available in Tokunoshima**

Yuri Tabata (Visiting Nursing Office, Tokunoshima Tokusyuukai Hospital)

**最期まで離島で良く生きる、徳之島でできる在宅緩和ケア**  
 田畑 幸利 (徳之島徳洲会病院 訪問看護事業所)



## Meet the Experts ① (4号館 3F 会議室 436)

8:50-9:50 Meet the Experts 9

**ME9** Are current follow up strategies for head ad neck cancer still fit for purpose? **E**

Chair : Shigenori Kadowaki (Aichi Cancer Center Hospital, Department of Clinical Oncology)  
司会 : 門脇 重憲 (愛知県がんセンター 薬物療法部)

**ME9** Are current follow up strategies for head ad neck cancer still fit for purpose?

Hisham M Mehanna (Institute of Head and Neck Studies and Education, University of Birmingham)

10:10-11:10 Meet the Experts 10

**ME10** What is the next cutting-edge treatment for urothelial carcinoma ? **E**

Chairs : Ken-ichi Tabata (Kitasato University Kitasato Institute Hospital Department of Urology)  
Keita Uchino (NTT Medical Center Tokyo, Department of Medical Oncology)

司会 : 田畑 健一 (北里大学北里研究所病院 泌尿器科)  
内野 慶太 (NTT東日本関東病院 腫瘍内科)

**ME10** What is the next cutting-edge treatment for urothelial carcinoma ?

Thomas B. Powles (Barts Cancer Institute, United Kingdom)

Day 1 (Thu)  
 Day 2 (Fri)  
 Day 3 (Sat)  
 On-demand  
 Room 1  
 Room 2  
 Room 3  
 Room 4  
 Room 5  
 Room 6  
 Room 7  
 Room 8  
 Room 9  
 Room 10  
 Room 11  
 Room 12  
 Room 13  
 Meet the Experts  
 Poster

**Meet the Experts ② (4号館 3F 会議室 437)**

8:50-9:50 Meet the Experts 11

**ME11 Essence of a Investigator, my message to young doctors in gynecologic oncology** **E**

Chairs : Shiro Suzuki (Aichi Cancer Center Hospital, Department of Gynecologic Oncology)  
 Mayu Yunokawa (The Cancer Institute Hospital of JFCR)  
 司会 : 鈴木 史朗 (愛知県立がんセンター 婦人科)  
 温泉川 真由 (がん研有明病院 総合腫瘍科・婦人科)

**ME11 Essence of a Investigator, my message to young doctors in gynecologic oncology**  
 Kathleen N Moore (OU Stephenson Cancer Center)

10:10-11:10 Meet the Experts 12

**ME12 Dermatological approach to patients with cancer- The value of a multidisciplinary approach** **E**

Chair : Koji Matsumoto (Division of Medical Oncology, Hyogo Cancer Center)  
 司会 : 松本 光史 (兵庫県立がんセンター 腫瘍内科)

**ME12 Dermatological approach to patients with cancer- the value of a multidisciplinary approach**  
 Anisha B. Patel (Department of Dermatology, University of Texas MD Anderson Cancer Center)

15:00-16:00 Meet the Experts 13

**ME13 Antibody-drug conjugates: a pan-histologic revolution in the treatment of cancer** **E**

Chairs : Kazuki Nozawa (Department of Center for Cancer Genomics and Advanced Therapeutics, Breast Oncology, Aichi Cancer Center Hospital)  
 Hitomi Sakai (Advanced Cancer Translational Research Institute, Showa University)  
 司会 : 能澤 一樹 (愛知県がんセンター ゲノム医療センターがんゲノム医療室・乳腺科部)  
 酒井 瞳 (昭和大学 先端がん治療研究所)

**ME13 Antibody-drug conjugates: a pan-histologic revolution in the treatment of cancer**  
 Paolo Tarantino (Dana-Farber Cancer Institute)

ポスター① (3号館 B1F カスケード)

11:30-12:15 Poster Session 49

**P49** Gastrointestinal Cancer 9 (Other (Appendix Cancer, Anal Cancer, etc.))  
消化器 9 (その他 (虫垂、肛門管等))

P49-1 演題取下

**P49-2 Feasibility and Safety of Exercise in Rectal Cancer During Chemoradiation: A Systematic Review**

Emanuela C. K. Suchayo (Faculty of Medicine, Pelita Harapan University)

11:30-12:15 Poster Session 50

**P50** Gastrointestinal Cancer 10 (Colorectal Cancer 1)  
消化器 10 (大腸 1)

**P50-1 ctDNA as Promising Biomarker to Refine Adjuvant Treatment and Prognostic Value in Colorectal Cancer: Systematic Review**

Caroline Fricilia Jhoputri (Faculty of Medicine, University of Pelita Harapan)

**P50-2 White-Light versus Linked-Color Imaging For Colorectal Adenocarcinoma Detection: Systematic Review and Meta-Analysis**

Riona Sutanto (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)

**P50-3 Is Aspirin an excellent option to prevent colorectal adenoma risk: A Systematic Review**

Riona Sutanto (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)

**P50-4 PiRNA-823 as a Prognostic, Non-Invasive Biomarker in Colorectal Cancer: A Systematic Review**

Clarissa Ardalín Cendera (Faculty of Medicine, Pelita Harapan University)

**P50-5 The prognostic ability of immunoscore in patients with localized colon cancer: a systematic review and meta analysis**

Encore

John Lois Ulep Padayao (Section of Medical Oncology, Cancer Institute, St Luke's Medical Center)

**P50-6 Role of FOLFOXIRI and Bevacizumab Treatment for Patients with mCRC: A systematic Review and Meta-analysis**

Billie E Herijanto (Faculty of Medicine, Pelita Harapan University)

**P50-7 Efficacy and Safety of BRAF inhibitor therapy for elderly metastatic colorectal cancer patients with *BRAFV600E* mutation**

Hiroko Hasegawa (National Hospital Organization Osaka National Hospital Department of Gastroenterology and Hepatology)

高齢者 BRAF 変異陽性大腸癌に対する BRAF 阻害剤の治療成績

長谷川 裕子 (大阪医療センター 消化器内科)

**P50-8 Total neoadjuvant therapy (TNT) with short course RT for locally advanced rectal cancer; single institution experience**

Kentaro Sawada (Department of Medical Oncology, Kushiro Rosai Hospital)

澤田 憲太郎 (釧路労災病院 腫瘍内科)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Poster Experts

Day 1 (Thu) | Day 2 (Fri) | Day 3 (Sat) | On-demand | Room 1 | Room 2 | Room 3 | Room 4 | Room 5 | Room 6 | Room 7 | Room 8 | Room 9 | Room 10 | Room 11 | Room 12 | Room 13 | Meet the Experts | Poster

11:30-12:15 Poster Session 51

- |              |  |
|--------------|--|
| <b>P51</b>   | Gastrointestinal Cancer 11 (Colorectal Cancer 2)<br>消化器 11 (大腸 2)  |
| <b>P51-1</b> | <p><b>Retrospective study of 1st-line doublet chemotherapy + either cetuximab or panitumumab for left-sided colorectal cancer</b></p> <p>Ryosuke Kawagoe (Department of Gastroenterology, University of Tsukuba Hospital)<br/>川越 亮承 (筑波大学医学医療系 消化器内科)</p>  |
| <b>P51-2</b> | <p><b>The efficacy of chemotherapy for colorectal cancer with early recurrence after adjuvant chemotherapy</b></p> <p>Dai Okemoto (Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University / Hirakata Municipal Hospital)<br/>楠本 大 (大阪医科大学大学病院 化学療法グループ / 枚方市民病院)</p>  |
| <b>P51-3</b> | <p><b>iPS cell-derived <math>\gamma\delta</math> T cells as a novel immunotherapy for colorectal cancer</b></p> <p>Ryoko Futai (Department of gastroenterology, Kobe University Hospital / Department of iPS cell applications, Kobe University graduate school of medicine)<br/>二井 諒子 (神戸大学医学部付属病院 消化器内科 / 神戸大学大学院医学研究科 幹細胞医学分野)</p>  |
| <b>P51-4</b> | <p><b>Current findings and future directions of comprehensive genome profiling for patients with colorectal cancer</b></p> <p>Hajime Nakamura (Department of Medical Oncology, Sapporo Medical University School of Medicine)<br/>中村 元 (札幌医科大学医学部 腫瘍内科学講座)</p>   |
| <b>P51-5</b> | <p><b>Is anti-EGFR therapy effective for neoRAS wild-type colorectal cancer?</b></p> <p>Shintaro Hashimoto (Department of Surgery, Kurashiki central hospital)<br/>橋本 紳太郎 (倉敷中央病院 外科)</p>  |
| <b>P51-6</b> | <p style="background-color: #4a7ebb; color: white; padding: 2px;"><b>Encore</b></p> <p><b>Real-world effectiveness of EGFR inhibitors in patients with early-onset (eo), metastatic colorectal cancer (mCRC)</b></p> <p>Hideaki Bando (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)<br/>坂東 英明 (国立がん研究センター東病院 消化管内科)</p> |
| <b>P51-7</b> | <p><b>Comparison of chemotherapy-induced peripheral neuropathy between FOLFOX and CAPOX in Stage II/III colorectal cancer</b></p> <p>Ryo Sugiyama (Asahi Kasei Pharma Corporation, Clinical Development Center, Clinical Planning Department)<br/>杉山 諒 (旭化成ファーマ株式会社 臨床開発センター 臨床計画部)</p>  |
| <b>P51-8</b> | <p><b>Vitamin D3 and <i>Lysiphylum strychnifolium</i> extract are immunomodulator in colorectal carcinoma-bearing models</b></p> <p>Sophida Sukprasert (Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand)</p>   |
| <b>P51-9</b> | <b>演題取下</b>  |

11:30-12:15 Poster Session 52

- |              |   |
|--------------|---|
| <b>P52</b>   | Gastrointestinal Cancer 12 (Colorectal Cancer 3)<br>消化器 12 (大腸 3)   |
| <b>P52-1</b> | <p><b>High Impact on sexual dysfunction after surgical treatment in Colo-rectal Cancer</b></p> <p>Rakesh Kumar (Department of Psychiatry)</p> |

P52-2	<b>Overall survival in liver transplant for unresectable colorectal liver metastases in adults: Systematic Review</b> Gregorius G Djatmiko (Faculty of Medicine, Pelita Harapan University)	Day 1 (Thu)
P52-3	<b>Cases of hyperammonemia during chemotherapy for colorectal cancer</b> Junichiro Nasu (Okayama Saiseikai General Hospital, Department of Internal Medicine) 那須 淳一郎 (岡山済生会総合病院 内科)	Day 2 (Fri)
P52-4	<b>The efficacy of adjuvant chemotherapy after TME without lateral pelvic node dissection for lower rectal cancer</b> Shin Kameishi (Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University / Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University / Moriguchi Keijinkai Hospital) 亀石 真 (大阪医科薬科大学病院 化学療法センター / 大阪医科薬科大学病院 第二内科 / 守口敬仁会病院)	Day 3 (Sat) On-demand
P52-5	<b>A retrospective analysis of the prognostic impact of KRAS G12D mutation in patients with metastatic colorectal cancer</b> Toshiharu Hirose (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital) 廣瀬 俊晴 (国立がん研究センター中央病院 消化管内科)	Room 1 Room 2
P52-6	<b>Effect of locoregional recurrence and optimal timing of palliative radiotherapy for unresectable recurrent rectal cancer</b> Tomoki Sakakida (Department of Clinical Oncology, Aichi Cancer Center Hospital) 柿田 智喜 (愛知県がんセンター 薬物療法部)	Room 3 Room 4
P52-7	<b>Demographic, Clinical and Mutational Profiles of Colorectal Cancer Patients from 2017 to 2021 in The Medical City</b> Laurice T Arayan (Augusto P. Sarmiento Cancer Institute, The Medical City)	Room 5 Room 6
P52-8	<b>Investigation of dihydropyrimidine dehydrogenase in colorectal carcinoma-bearing models</b> Jasmine Promruksa (Medical Program in Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand)	Room 7 Room 8
P52-9	<b>KIAA1199 Influences Prognosis in Patients with Colorectal Cancer in Vietnam</b> Hong-Quan Duong (Hanoi University of Public Health)	Room 9

11:30-12:15 Poster Session 53

P53	Gastrointestinal Cancer 13 (Colorectal Cancer 4) 消化器 13 (大腸 4)	Room 10
P53-1	<b>THE VALUE OF HIGH-RESOLUTION T2-WEIGHTED MRI TO EVALUATE STAGING RECTAL CANCER</b> Tran Duc Huy (Radiology Center, Bach Mai Hospital)	Room 11 Room 12
P53-2	<b>Next-Generation Sequencing In Screening For Colorectal Cancer: A Systematic Review</b> Mario P Winata (Faculty of Medicine, Pelita Harapan University)	Room 13
P53-3	<b>Triplet-Therapy for BRAF V600E-Mutated Metastatic Colorectal Cancer: a Systematic Review of RCT</b> Edellin F Lokanata (Faculty of Medicine, Pelita Harapan University)	Meet the Poster Experts

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

P53-4	<b>Safety and efficacy of Pembrolizumab in patients with Microsatellite Instability Colorectal Cancer: A Systematic Review</b> Timothy Chan (Faculty of Medicine UPH)
P53-5	<b>Overall effect of Nivolumab plus Ipilimumab on Colorectal Cancer: a Systematic review and meta analysis</b> Ayu I.U. Amalia (Faculty of Medicine, Pelita Harapan University)
P53-6	<b>Trifluridine/tipiracil (TAS-102) vs Placebo in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis</b> Cecilia E.O.L. Hutauruk (Faculty of Medicine, Pelita Harapan University)
P53-7	<b>SFRP2 DNA Methylation as a Biomarker for The Early Detection of Colorectal Cancer: A Systematic Review and Meta-Analysis</b> I Gede Krisna Arim Sadeva (Faculty of Medicine, Udayana University)
P53-8	<b>Efficacy of Bevacizumab in Combination with Chemotherapy Protocols for Colonic Neoplasms: A Systematic Review</b> Albertus Marga Nayotama (Faculty of Medicine Pelita Harapan University)
P53-9	<b>A case of rectal melanoma with a marked response to anti-PD-1 antibody nivolumab without surgical resection</b> Tomohiro Matsumoto (Department of Clinical Oncology, Akita Red Cross Hospital) 松本 朋大 (秋田赤十字病院 腫瘍内科)
11:30-12:15 Poster Session 54	
<b>P54</b>	<b>Gastrointestinal Cancer 14 (Colorectal Cancer 5)</b> 消化器 14 (大腸 5)
P54-1	<b>Capecitabine with or without Bevacizumab as first line treatment for elderly patients with metastatic colorectal cancer</b> Hidenori Shibata (Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine) 柴田 英典 (東京慈恵会医科大学附属病院 消化器・肝臓内科)
P54-2	<b>The effectiveness of plasma RAS mutation analysis using OncoBEAM™ RAS CRC Kit for Colorectal Cancer</b> Katsuyoshi Ando (Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University) 安藤 勝祥 (旭川医科大学 内科学講座 消化器内科学分野)
P54-3	<b>The Effect of Gut Microbiome-Dependent Metabolic Pathways on Developing Risk of Lethal Colorectal Cancer</b> Angela Maria Tandun (Faculty of Medicine, Pelita Harapan University)
P54-4	<b>ALPHA-FETOPROTEIN-SECRETING MUCINOUS ADENOCARCINOMA OF THE RECTUM: A CASE REPORT</b> Rachelle Diane B. Maravilla (Section of Medical Oncology, St. Luke's Medical Center Philippines)
P54-5	<b>Bevacizumab with chemotherapy in colorectal cancer: A systematic review</b> Hasti H. Tolani (Faculty of Medicine, Pelita Harapan University, Indonesia)
P54-6	<b>Safety and Efficacy of Cetuximab and Panitumumab in Patients with Colorectal Cancer: A Systematic Review</b> Raymonth Suhardi (Faculty of Medicine, Pelita Harapan University, Tangerang,Banten, Indonesia)

- P54-7 Efficacy of various adjuvant chemotherapy in colorectal cancer**  
 Jasneet Gill (Department of Medical Oncology, Hamidia Hospital)
- P54-8 Efficacy and Safety of Capecitabine in Patients with Colon Cancer: A Systematic Review**  
 Viola T. Herwi (Faculty of Medicine, Pelita Harapan University)
- P54-9 Severe Adverse Events Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report**  
 Yoshitomo Ashitate (Urakawa Red Cross Hospital)  
**Capecitabineにより重篤な副作用を来した Dihydropyrimidine Dehydrogenase (DPD) 欠損症が疑われた 1 例**  
 芦立 嘉智 (浦河赤十字病院 外科)

11:30-12:15 Poster Session 55

- P55 Medical Case Report 5 (Gastrointestinal Tract 2)**  
 ケースレポート 5 (消化器 2)
- P55-1 A case report of secondary findings of a *BRCA2* variant in metastatic colon cancer**  
 Shigeru Tanaka (Department of Clinical Laboratory/General Medicine, Okazaki City Hospital)  
**転移性大腸癌における *BRCA2* バリエント二次的所見の 1 例**  
 田中 繁 (岡崎市民病院 臨床検査科/総合内科)
- P55-2 A case of colorectal cancer with lung metastases that had clinical complete response treated with XELOX plus bevacizumab**  
 Takahiro Kamiga (Department of Surgery, Shendai Tokushukai Hospital)  
**XELOX+bevacizumab療法が著効して clinical complete responseとなったS状結腸癌の同時性肺転移の 1 例**  
 神賀 貴大 (仙台徳洲会病院 外科)
- P55-3 Treatment Sequence for Moving the Needle in a HER2-Positive Metastatic Colorectal Cancer with High Liver Tumor Burden**  
 Yoko Nagata (Department of Medical Oncology, Matsuyama Red Cross Hospital)  
 長田 陽子 (松山赤十字病院 臨床腫瘍科)
- P55-4 A case of Turcot syndrome presenting Lynch-like syndrome and glioblastoma**  
 Ayako Togawa (Gastroenterology, Kurashiki Central Hospital)  
**Lynch-like症候群に膠芽腫を合併した Turcot症候群の一例**  
 戸川 文子 (倉敷中央病院 消化器内科)
- P55-5 A case of metastatic colon cancer with *EGFR* gene amplification and *KRAS* mutation benefited from panitumumab rechallenge**  
 Taro Sato (Department of Medical Oncology, Kyorin University Faculty of Medicine)  
 佐藤 太龍 (杏林大学医学部 腫瘍内科学)
- P55-6 A case of dermatomyositis during chemotherapy for postoperative recurrence of sigmoid colon cancer**  
 Yukito Koike (Gastroenterology, Kansairosai Hospital)  
**S状結腸癌術後再発に対する化学療法中に皮膚筋炎を発症した 1 例**  
 小池 侑紀仁 (関西労災病院 消化器内科)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

**P55-7** **A case of granulocyte colony stimulating factor (G-CSF) - associated aortitis in a man with sigmoid colorectal cancer**  
Yoshimitsu Taguchi (Department of Internal Medicine, Division of Medical Oncology, Tokyo Saiseikai Central Hospital)

**G-CSF 誘発性大動脈炎を発生した HIV 併存大腸癌の一例**  
田口 佳光 (東京都済生会中央病院 腫瘍内科)

**P55-8** **MSI-high colon cancer case with driver gene alterations and germline SDHB truncation showing a remarkable ICI response**  
Naoki Ashikawa (Department of Cancer Genomic at Yamagata University)

**複数の Driver 変異を有しつつ ICI が著効した生殖細胞系列 SDHB 陽性の MSI-high 結腸癌の 1 例**  
芦川 直輝 (山形大学 癌ゲノム管理室)

11:30-12:15 Poster Session 56

**P56** Medical Case Report 6 (Gastrointestinal Tract 3)  
ケースレポート 6 (消化器 3)

**P56-1** **A Case of Splenic Flexure of Colon Cancer in A Fifteen Year Old Boy- Challenges faced during the treatment**  
Santhosh Meedimale (Department of Medical Oncology, IMS , SUM Hospital)

**P56-2** **Papillary Thyroid Carcinoma and Gastrointestinal Stromal Tumor – Metachronous Tumor: A Case Report**  
Maurice Jeanne R. Aguero (Davao Regional Medical Center)

**P56-3** **Imatinib for Unresectable Gastrointestinal Stromal Tumors – A Case Report**  
Dwijayanti T. Anggraeni (Medical Doctor of International SOS Jakarta)

**P56-4** **Chemoradiotherapy-induced pleurosdesis; a rare cause of hemopneumothorax**  
Kosuke Sagara (Department of Medical Oncology, Fukuoka Wajiro Hospital)

**化学放射線療法による胸膜癒着が誘因と考えられた血気胸の一例**  
相良 浩輔 (福岡和白病院 腫瘍内科)

**P56-5** **門脈腫瘍栓を伴う肝細胞癌と直腸癌肺転移に対してアテゾリズマブ+ペバシズマブ療法が奏効した 1 例**  
Yoshitaka Inaba (Department of Diagnostic and Interventional Radiology, Aichi Cancer Center)  
稲葉 吉隆 (愛知県がんセンター 放射線診断・IVR部)

**P56-6** **A case of advanced HCCs with pCR after hepatic resection following Atezolizumab+Bevacizumab combination therapy**  
Kunihiko Tajima (Cancer Center, Yamaguchi University Hospital / Department of Gastroenterology, Yamaguchi Prefectural Grand Medical Center)

**アテゾリズマブ+ペバシズマブ併用療法後、肝切除をおこない病理学的完全奏功 (pCR) が得られた多発進行肝細胞癌の 1 例**  
田島 邦彦 (山口大学医学部附属病院 腫瘍センター / 山口県立総合医療センター 消化器内科)

**P56-7** **A case of unresectable advanced gastric cancer resected by conversion surgery after chemotherapy with nivolumab**  
Shingo Ito (Department of Surgery, Ikegami General Hospital)

**FOLFOX + ニボルマブ療法後に conversion surgery を施行し pCR を得た進行胃癌の 1 例**  
伊藤 慎吾 (池上総合病院 外科)



**P56-8 A case of symptomatic pancreatitis after nivolumab plus SOX therapy for advanced gastric cancer**

Takashi Matsumura (Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center)

**進行胃癌に対するニボルマブ+SOX療法後に発症した症候性膵炎の一例**

松村 尚 (九州がんセンター 消化管腫瘍内科)

17:10-17:55 Poster Session 57

- P57** Hepatobiliary/Pancreatic Cancer 1 (Liver Cancer 1)  
肝胆膵 1 (肝臓 1)
- P57-1 Relationship among agricultural vulnerability to hepatocellular carcinoma Incidence in Rural population in India**  
Ankush Kumar (Shakuntla Hospital And Research Center)
- P57-2 演題取下**
- P57-3 Role of combination of cinnamaldehyde and resveratrol on 7,12- dimethyl benz (a) anthracene-induced liver cancer in rats**  
Dinesh Dayam, Rahul Kumar (Department of Zoology, J K College)
- P57-4 To investigate the role of *NOP16* in HCC cells through bioinformatics analysis**  
Mei-Ling Chiu (Department of Pharmacy Chia-Nan University of Pharmacy and Science)
- P57-5 NUCB-2 involved in Endoplasmic Stress and Metabolic signaling pathway in HCC by Bioinformatics analysis**  
Wei-Ting Wu (Department of Pharmacy Chia-Nan University of Pharmacy and Science)
- P57-6 The Cost-Effectiveness of Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma from a Canadian Perspective**  
Mohammad Salman Hussain (Department of Pharmacology, Jamia Hamdard)
- P57-7 演題取下**
- P57-8 The Efficacy and Safety of Lenvatinib on Patients with Hepatocellular Carcinoma: A Systematic Review of RCTs**  
Mikael H. Wibisono (University of Pelita Harapan)
- P57-9 Meta Analysis of Lenvatinib vs. Sorafenib Following Atezolizumab+Bevacizumab in Advanced Hepatocellular Carcinoma**  
Refael A. Budiman (Faculty of Medicine, Universitas Indonesia, Indonesia)

17:10-17:55 Poster Session 58

- P58** Hepatobiliary/Pancreatic Cancer 2 (Liver Cancer 2)  
肝胆膵 2 (肝臓 2)
- P58-1 Prognostic Role of NLR in HCC Patients Underwent Stereotactic Body Radiotherapy: A Meta-Analysis**  
Devina A. Halim (Faculty of Medicine, Pelita Harapan University)
- P58-2 Epithelioid Hemangioendothelioma of the Liver: A Case Report**  
Cristina G Domingo (Cancer Institute St Lukes Medical Center Quezon City)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Day 1 (Thu)	P58-3	<b>Real World Data of Hepatocellular Carcinoma on Systemic Treatment Between 2 Hospitals in the Philippines</b> Charles Jeffrey L Tan (St. Luke's Medical Center Quezon City / St. Luke's Medical Center Global City)
Day 2 (Fri)	P58-4	<b>Efficacy and Safety of Ramucirumab on Hepatobiliary Neoplasm: A Systematic Review</b> Jeanes Jeanes (Pelita Harapan University)
Day 3 (Sat)	P58-5	<b>The study of the effects of Chelidonium majus on the growth of cancer cells</b> Dashkhorol Davaadorj (Department of Medical Oncology, Mongolian National University of Medical Science)
On-demand	P58-6	<b>Efficacy and safety of Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma: A systematic review</b> Yalimo P. Yogobi (Faculty of Medicine, Pelita Harapan University, Indonesia)
Room 1	P58-7	<b>Advances in chemotherapy influenced treatment choice and hospital days for advanced hepatocellular carcinoma</b> Aya Seko (Kyoto City Hospital) 薬物治療の進歩が進行肝細胞癌の治療選択に与えた影響と、治療別の入院通院日数の現状 瀬古 彩 (京都市立病院 消化器内科)
Room 2	P58-8	<b>Best alternative conduit in unusable recipient's hepatic artery for liver transplantation: A network meta-analysis</b> Citra Aryanti (Hasanuddin University)
Room 3		
Room 4		
Room 5		
Room 6		17:10-17:55 Poster Session 59
Room 7	P59	Hepatobiliary/ Pancreatic Cancer 3 (Liver Cancer 3) 肝胆胰 3 (肝臓 3)
Room 8	P59-1	<b>Comparing Efficacy and Safety of Lenvatinib to Sorafenib for the Hepatocellular Carcinoma Treatment: A Systematic Review</b> Sherina Kosayuz (Department of Medicine, Pelita Harapan University)
Room 9	P59-2	<b>Efficacy and Safety of Pembrolizumab as a Potential Treatment for Patients with Colorectal Cancer: A Meta-Analysis</b> Kho Jesselyne Aurelia Santoso (Faculty of Medicine, Pelita Harapan University)
Room 10	P59-3	<b>A Comparison of Overall Survival of HCC advance stage from Viral Hepatitis between Systemic Group and Palliative Group</b> Piyaporn Phetchoo (Department of Medical Oncology, Internal Medicine, Chaophrayayommarat Hospital, Thailand)
Room 11	P59-4	演題取下
Room 12	P59-5	<b>A case underwent locoregional treatment during atezolizumab/bevacizumab combined therapy for hepatocellular carcinoma</b> Takatoshi Nawa (Department of Gastroenterology, Higashiosaka-city Medical Center) 肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法中に食道静脈瘤治療と肺転移部放射線治療を行った一例 名和 誉敏 (市立東大阪医療センター 消化器内科)
Room 13		
Meet the Experts		
Poster		

P59-6	<b>Sorafenib as a late line treatment after Regorafenib failure in a patient with refractory Hepatocellular Carcinoma</b> Ami Kato (Tokyo Saiseikai Central Hospital) 加藤 亜美 (東京都済生会中央病院)
P59-7	<b>Multimodal Therapy Using Atezolizumab and Bevacizumab for Multiple Hepatocellular Carcinomas Adjacent to Major Vessels</b> Takahisa Fujikawa (Department of Surgery, Kokura Memorial Hospital) 藤川 貴久 (小倉記念病院 外科)
17:10-17:55 Poster Session 60	
<b>P60</b>	Hepatobiliary/ Pancreatic Cancer 4 (Gallbladder and Biliary Tract Cancer) 肝胆膵 4 (胆嚢・胆道)
P60-1	<b>Short-term outcomes of gemcitabine, cisplatin, and durvalumab in previously treated unresectable biliary tract cancer</b> Takeshi Okamoto (Cancer Institute Hospital, Japanese Foundation for Cancer Research) 岡本 武士 (がん研究会有明病院 肝胆膵内科)
P60-2	<b>Experience using durvalumab for advanced biliary tract cancer</b> Daiki Sone (Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine) 曾根 大暉 (京都府立医科大学附属病院 消化器内科)
P60-3	<b>Single-center real-world data on durvalumab plus gemcitabine and cisplatin for advanced biliary tract cancer</b> Tomoyuki Satake (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East) 佐竹 智行 (国立がん研究センター東病院 肝胆膵内科)
P60-4	<b>Gemcitabine and cisplatin plus durvalumab for advanced biliary tract cancers: A single-center retrospective study</b> Nozomu Ogura (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital) 小倉 望 (国立がん研究センター中央病院 肝胆膵内科)
P60-5	<b>Clinical Outcome of Durvalumab plus Gemcitabine and Cisplatin as First-line therapy in Biliary Tract Cancer</b> Ikuhiro Kita (Department of Medical Oncology and Chemotherapy, Takamatsu Red Cross Hospital / Department of Medical Oncology, Kagawa University Hospital / Department of Oncological Medicine, Kochi Health Sciences Center) 喜田 行洋 (高松赤十字病院 腫瘍内科 / 香川大学医学部附属病院 腫瘍内科 / 高知医療センター 腫瘍内科)
P60-6	<b>Treatment outcomes with gemcitabine, cisplatin, and durvalumab in patients with advanced biliary tract cancer</b> Kenji Ikezawa (Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute) 池澤 賢治 (大阪国際がんセンター 肝胆膵内科)
P60-7	<b>Treatment Outcomes of Unresectable Intrahepatic Cholangiocarcinoma</b> Akihiro Deguchi (Division of Gastroenterology, Kagawa Rosai Hospital) 出口 章広 (香川労災病院 消化器内科)

Day 1 (Thu)  
 Day 2 (Fri)  
 Day 3 (Sat)  
 On-demand  
 Room 1  
 Room 2  
 Room 3  
 Room 4  
 Room 5  
 Room 6  
 Room 7  
 Room 8  
 Room 9  
 Room 10  
 Room 11  
 Room 12  
 Room 13  
 Meet the  
 Experts  
 Poster

**P60-8 Experience of using Durvalumab + Gemcitabine + Cisplatin for advanced biliary tract cancer in our hospital**  
 Hidekazu Kuramochi (Department of Chemotherapy and Palliative Care, Tokyo Women's Medical University Hospital)

**進行胆道癌に対するデュルバルマブ+ゲムシタビン+シスプラチン療法の当施設での使用経験**  
 倉持 英和 (東京女子医科大学病院 化学療法・緩和ケア科)

**P60-9 Durvalumab plus gemcitabine and cisplatin for advanced biliary tract cancer: An initial experience in our hospital**  
 Satoshi Matsukuma (Department of Surgery, JCHO Tokuyama Central Hospital)  
 松隈 聡 (徳山中央病院 外科)

17:10-17:55 Poster Session 61

**P61 Hepatobiliary/ Pancreatic Cancer 5 (Pancreatic Cancer 1)**  
 肝胆膵 5 (膵臓 1)

**P61-1 Prognostic Value of Metabolic Tumor Volume in Patients with Resectable Pancreatic Cancer: A Meta-Analysis**  
 Heru S. Koerniawan (Department of Surgery, Faculty of Medicine, Pelita Harapan University)

**P61-2 Efficacy of Pembrolizumab with Standard Treatment vs. Standard Treatment in Pancreatic Cancer: A Systematic Review**  
 Kenza Y. Rubismo (Faculty of Medicine, University of Pelita Harapan, Tangerang, Indonesia)

**P61-3 Conversion surgery for PALB2 germline mutation-positive pancreatic cancer treated with mFOLFIRINOX therapy**  
 Ryusuke Shibata (Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences)  
**mFOLFIRINOX療法が奏効し conversion surgeryが可能であった gPALB2 変異陽性膵癌の一例**  
 柴田 隆佑 (鹿児島大学大学院医歯学総合研究科 消化器疾患・生活習慣病学)

**P61-4 Assessment of Frailty in Patients with UR-M and Recurrent Pancreatic Cancer in Our Department**  
 Hiroto Matsui (Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine)  
 松井 洋人 (山口大学 消化器・腫瘍外科学)

**P61-5 Objective indicator for the induction of 2L chemotherapy after nab-PTX+GEM in patients with advanced pancreatic cancer**  
 Kiyotsugu Iede (Department of Clinical Oncology, Higashiosaka City Medical Center)  
 家出 清継 (市立東大阪医療センター 臨床腫瘍科)

**P61-6 The frequency of hypozincemia and the effect of zinc supplementation in patients with unresectable pancreatic cancer**  
 Yusuke Seiki (Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute)  
 清木 祐介 (大阪国際がんセンター 肝胆膵内科)

**P61-7 Second-line chemotherapy for advanced pancreatic cancer (nal-IRI/FL vs mFOLFIRINOX): A single center retrospective study**  
 Toru Otsuru (Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center)  
**当院における進行膵癌における 2次治療の検討 (nal-IRI/FL and modified FOLFIRINOX)**  
 大鶴 徹 (四国がんセンター 消化器内科)

**P61-8** **Impact of time from diagnosis to chemotherapy on prognosis in advanced pancreatic cancer**  
Tsutomu Nishida (Toyonaka Municipal Hospital)  
西田 勉 (市立豊中病院 消化器内科)

17:10-17:55 Poster Session 62

**P62** Hepatobiliary/ Pancreatic Cancer 6 (Pancreatic Cancer 2)  
肝胆膵 6 (膵臓 2)

**P62-1** **How to characterize Tempeh as a suggestion in Nutritional Therapy for Pancreatic Cancer?**  
Andi Nursanti (Wallacea University)

**P62-2** **The association between SLFN11 expression and prognosis in metastatic pancreatic ductal adenocarcinoma**  
Takeaki Nakamura (Division of Cancer Center, Hokkaido University Hospital)  
**遠隔転移を有する膵癌におけるSLFN11発現と予後の関連性の検討**  
中村 起晶 (北海道大学病院 腫瘍センター)

**P62-3** **Usefulness of an S-1 dosage formula in adjuvant chemotherapy for pancreatic cancer: a retrospective analysis**  
Satoshi Matsukuma (Department of Surgery, JCHO Tokuyama Central Hospital)  
松隈 聡 (徳山中央病院 外科)

**P62-4** **Factors influencing second-line treatment transition in chemotherapy for pancreatic cancer**  
Tatsuma Morikita (Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital)  
**膵癌の薬物療法における2次治療移行に影響する要因の検討**  
森北 辰馬 (済生会 熊本病院 総合腫瘍科)

**P62-5** **Treatment outcomes of FOLFOX therapy as late-line therapy in unresectable pancreatic cancer**  
Tatsuki Hirai (Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research)  
平井 達基 (がん研究会有明病院 肝胆膵内科)

**P62-6** **Pancreatic cancer patients who continued drug therapy at other hospitals**  
Yasushi Kojima (Department of Gastroenterology, Center Hospital of the National Center for Global Health and Medicine)  
小島 康志 (国立国際医療研究センター病院 消化器内科)

**P62-7** **The utility of liquid biopsy in patients with advanced pancreatic cancer**  
Makiko Urabe (Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute)  
占部 真貴子 (大阪国際がんセンター 肝胆膵内科)

**P62-8** **Actual situations and problems of care for pancreatic cancer in community medicine**  
Ryuta Ohira (Saka General Hospital)  
大衡 竜太 (坂総合病院)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the  
Experts

Poster

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

17:10-17:55 Poster Session 63

**P63** Clinical Trial Facilitation Program 1 (Biostatistics)  
臨床試験推進プログラム 1 (生物統計)

**P63-1** **A targeted review of worldwide indirect comparison guidelines and best practices**  
Raf De Moor (Value, Evidence and Access Department, IMAT, Janssen Pharmaceutical K.K.)

17:10-17:55 Poster Session 64

**P64** Clinical Trial Facilitation Program 2 (Clinical Trial Support)  
臨床試験推進プログラム 2 (臨床試験支援)

**P64-1** **Efforts to improve the drug accessibility using the patient-proposed healthcare services -A company perspective-**

Naomi Hayase (Medical Affairs Division, Novartis Pharma K.K.)

患者申出療養制度を利用した治療機会提供の取り組み  
—MAP(Managed Access Programs) を通して薬剤提供している製薬企業の立場から—  
早瀬 奈緒美 (ノバルティスファーマ株式会社 メディカル・アフェアーズ本部)

**P64-2** **がん臨床研究グループのホームページ制作におけるペルソナとカスタマージャーニーマップ作成の重要性**

Kentaro Kawakami (Department of Medical Oncology, Keiyukai Sapporo Hospital / WJOG Web Site Renewal Committee)

川上 賢太郎 (恵佑会 札幌病院 腫瘍内科 / WJOG ホームページリニューアル委員会)

**P64-3** **Why are protocol-related queries in Japan remarkably increased compared to other regions? Survey targeting CRCs and CRAs**

Yayoi Kondo (IQVIA Services Japan K.K.)

日本の臨床試験においてプロトコル関連質問数が海外と比較して突出して多い背景：  
CRC・CRAを対象としたアンケート調査結果  
近藤 やよい (IQVIAサービシーズ ジャパン株式会社)

17:10-17:55 Poster Session 65

**P65** Clinical Trial Facilitation Program 3 (Trials in Progress)  
臨床試験推進プログラム 3 (Trials in Progress)

**P65-1** **Safety and Pharmacokinetics (PK) of TAR-210 in Japanese with Bladder Cancer and Select FGFR Alterations: Phase 1 Study**

Kazuo Nishimura (Department of Urology, Osaka International Cancer Institute)

特定のFGFR遺伝子異常を有する日本人膀胱癌患者を対象としたerdafitinib膀胱内送達システム (TAR-210) の安全性及び薬物動態を評価する第1相試験  
西村 和郎 (大阪国際がんセンター 泌尿器科)

**P65-2** **Phase II Study of Local Therapy for Oligo-Progressive disease during Immuno-Chemotherapy in Non-Small Cell Lung Cancer**

Taichi Miyawaki (Department of Respiratory Medicine, Juntendo University Graduate School of Medicine)

進行非小細胞肺癌における初回復合免疫療法後のOligo-Progressive diseaseに対する局所療法と免疫チェックポイント阻害剤による集学的治療の有効性を検討する第II相試験  
宮脇 太一 (順天堂大学医学部附属順天堂医院 呼吸器内科)

- P65-3** **Perfume trial: Phase II trial of binimetinib in patients with BRAF fusion-positive low-grade glioma or pancreatic cancer**  
Tomoyuki Satake (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)  
**BRAF** 融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膀胱癌に対するビニメチニブの第II相医師主導治験  
佐竹 智行 (国立がん研究センター東病院 肝胆膵内科)
- P65-4** **Pembrolizumab Plus Platinum and GEmcitabine as First Line Treatment of Recurrent Head and Neck Squamous Cell Carcinoma**  
Wan Zamaniah Binti Wan Ishak (Clinical Oncology Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia)
- P65-5** **A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC (NCT05773092)**  
Darren Wan-Teck Lim (Division of Medical Oncology, National Cancer Centre Singapore)
- P65-6** **Efficacy and safety of ACupuncture in breast cancer patients with Taxane-induced peripheral neurotoxicity**  
Hiroto Ishiki (National Cancer Center Hospital)  
**がん患者のタキサン誘発性末梢神経障害性疼痛に対する鍼灸治療の有効性および安全性の検討**  
石木 寛人 (国立がん研究センター中央病院)

17:10-17:55 Poster Session 66

- P66** Clinical Trial Facilitation Program 4 (Other)  
臨床試験推進プログラム 4 (その他)
- P66-1** **SKYWALKER study: Feasibility of Performing RWD Analysis Leveraging Electronic Medical Record Data in Japan**  
Kyosuke Seguchi (Department of Oncology, Kameda Medical Center)  
**SKYWALKER研究:日本における電子カルテデータを活用したリアルワールドデータ (RWD) 解析の実現可能性研究**  
瀬口 京介 (亀田総合病院 腫瘍内科)
- P66-2** **Statistical and clinical significance for anti-cancer treatment in confirmatory non-inferiority trial**  
Takashi Ikeno (Clinical Research Support Office, National Cancer Center Hospital East)  
**がんを対象とした検証的非劣性試験における統計学および臨床的有意差の検討**  
池野 敬 (国立がん研究センター東病院 臨床研究支援部門)
- P66-3** **Questionnaire Survey on Technical Support for the Research Project on Practical Research for Innovative Cancer Control**  
Yoshiyuki Sano (Practical Research for Innovative Cancer Control Management Office (PRIMO), National Cancer Center)  
**革新的がん医療実用化研究事業における技術支援に関するアンケート調査**  
佐野 慶行 (国立がん研究センター 革新的がん研究支援室)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

**ポスター② (4号館 1F 白鳥ホール (展示内))**

11:30-12:15 Poster Session 67

**P67** Multidisciplinary Team Program 1 (Interdisciplinary Approach to Cancer Care 1)  
多職種連携プログラム 1 (チーム医療 1)

**P67-1** **多職種で取り組んだラジオアイソトープ (RI) 室におけるペプチド受容体放射性核種療法 (PRRT) 中の急変時対応マニュアルの作成**  
Etsuko Hattori (Department of Nursing, Kansai Electric Power Hospital)  
服部 悦子 (関西電力病院 看護部)

**P67-2** **Multidisciplinary Approach to Immune-Related Adverse Events Management: Initiatives and Achievements at Our Institution**  
Go Makimoto (Department of Allergy and Respiratory Medicine, Okayama University Hospital / Center for Clinical Oncology, Okayama University Hospital)  
**免疫関連有害事象に対する当院での多職種連携の取り組み**  
横本 剛 (岡山大学病院 呼吸器・アレルギー内科 / 岡山大学病院腫瘍センター)

11:30-12:15 Poster Session 68

**P68** Multidisciplinary Team Program 2 (Interdisciplinary Approach to Cancer Care 2)  
多職種連携プログラム 2 (チーム医療 2)

**P68-1** **Establishment of a cancer treatment system utilizing multidisciplinary collaboration in Niigata Prefecture**  
Masato Moriyama (Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences / Department of Pathophysiology, Faculty of Pharmacy, Niigata University of Pharmacy and Medical and Life Sciences)  
**新潟県における多分野・多職種連携を活用したがん診療体系の確立**  
森山 雅人 (新潟大学大学院医歯学総合研究科 腫瘍内科学分野 / 新潟薬科大学 薬学部病態生理学)

**P68-2** **Consideration of the Utility of Oncology Genome Medical Coordinators in the Workstyle Reform for Physicians**  
Junko Yokobori (Tokyo Medical and Dental University Hospital)  
**専従がんゲノム医療コーディネーターの医師働き方改革における有用性の考察**  
横堀 潤子 (東京医科歯科大学病院)

**P68-3** **Looking back of creating a new team, system and environment for cancer chemotherapy in preparation for hospital merger**  
Namiko Hirayasu (Kawanishi City Medical Center)  
**病院移転統合に向けた、がん化学療法に関連する新たなチーム、システム、周辺環境作りの軌跡を振り返って見えたもの**  
平安 奈美子 (川西市立総合医療センター)

**P68-4** **Efforts to increase the specialty and quantity in chemotherapy at a medium-sized hospital**  
Kayoko Ueda (Department of Pharmacy, Ajisu Kyoritsu Hospital)  
**中小規模病院でがん薬物療法の専門性を上げる取り組み**  
上田 華昌子 (阿知須共立病院 薬剤科)



P68-5 **Approach to geriatric assessment and locomotive syndrome for older patients with lung cancer in our department**

Rie Kawabe (Department of Respiratory Medicine, Saitama Red Cross Hospital)

**当科における肺癌患者を対象とした高齢者総合機能評価とがんロコモティブシンドロームへの取り組み**

川辺 梨恵 (さいたま赤十字病院 呼吸器内科)

P68-6 **がん専門病院におけるがんゲノムプロファイリング検査を含めた治験・臨床試験への多職種連携効果と今後の課題**

Masumi Yamaguchi (Department of Center for Cancer Genomics and Advanced Therapeutics, Aichi Cancer Center Hospital)

山口 真澄 (愛知県がんセンター ゲノム医療センター)

11:30-12:15 Poster Session 69

P69

Multidisciplinary Team Program 3 (Outpatient Chemotherapy)  
多職種連携プログラム 3 (外来化学療法)

P69-1 **Patient Acceptance Survey of Device Changes**

Kumi Nakamura (Aizawa Hospital)

**デバイス変化に対する患者の受け入れ調査**

中村 久美 (相澤病院)

P69-2 **Factual investigation and issues of nutritional evaluation for patients receiving outpatient chemotherapy**

Yuki Mouri (Nagasaki Atomic-Bomb Hospital, Outpatient Department)

**当院の外来化学療法を受ける患者の栄養評価の実態と課題**

毛利 祐紀 (長崎原爆病院 診療外来)

P69-3 **肺癌に対する GEM + nab-PTX 療法による末梢神経障害予防のための冷却法の検討**

Hiroshi Ichiki (Kagoshima University Hospital)

市来 博美 (鹿児島大学病院)

P69-4 **The utility of the outpatient by certified pharmacist**

Yuka Iwai (Department of Pharmacy, Tane General Hospital)

**がん薬物療法における薬剤師外来の有用性**

岩井 裕香 (多根総合病院 薬剤部)

P69-5 **オキサリプラチン点滴静注液を末梢静脈カテーテルから投与している患者の疼痛対策について**

Hikaru Haruki (The University of Tokyo Hospital)

春木 ひかる (東京大学医学部附属病院)

P69-6 **Chemotherapy-related hypersensitive reactions in outpatients administered with platinum compounds**

Madoka Minamoto (Teine Keijinkai Hospital)

**白金製剤における過敏反応の発生状況とその対応の実態**

源 まどか (手稲溪仁会病院 看護部)

P69-7 **外来化学療法室におけるコメディカルの関与について～irAEを見逃さないために～**

Miki Moriwa (Department of Nursing National Defense Medical College)

守岩 美紀 (防衛医科大学校 大学校病院 看護部)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Poster Experts

Poster

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

**P69-8 若手消化器内科医のがん薬物療法に対する意識調査**  
Toshikazu Moriwaki (Department of Gastroenterology and Hepatology, Kurashiki Central Hospital)  
森脇 俊和 (倉敷中央病院 消化器内科)

11:30-12:15 Poster Session 70

**P70** Multidisciplinary Team Program 4 (Other)  
多職種連携プログラム 4 (その他)

**P70-1 Assessment on Methotrexate-related Adverse Events in Patients with Leukemia and Lymphoma using FAERS**  
Hayata Morimoto (Department of Pharmacy, Tokyo Medical University Hospital)  
**悪性リンパ腫及び白血病患者に対するメトトレキサート療法における有害事象報告に及ぼす併用薬の影響 -大規模自発報告データベース FAERS を用いた解析-**  
森本 隼多 (東京医科大学病院 薬剤部)

**P70-2 MIRAY1 initiatives to promote breast cancer care and education for young doctors**  
Mai Onishi (Japanese Breast Cancer Society MIRAY1 / Department of Medical Oncology, National Cancer Center Hospital)  
**乳がん診療に関わる医師を対象とした若手グループ (MIRAY1) による乳がん診療活性化・若手育成の取り組みについて**  
大西 舞 (日本乳癌学会 MIRAY1 / 国立がん研究センター中央病院 腫瘍内科)

11:30-12:15 Poster Session 71

**P71** Multidisciplinary Team Program 5 (Professional Oncology Education)  
多職種連携プログラム 5 (がんプロ)

**P71-1 腫瘍内科専門医の育成に関する、新専門医制度を念頭に置いた大学の取り組み**  
Satoru Aoyama (Department of Clinical Oncology, Tokyo Medical and Dental University Graduate School of Medicine / Department of Precision Cancer Medicine, Tokyo Medical and Dental University Hospital)  
青山 慧 (東京医科歯科大学大学院 医歯学総合研究科 臨床腫瘍学分野 / 東京医科歯科大学病院 がんゲノム診療科)

11:30-12:15 Poster Session 72

**P72** Multidisciplinary Team Program 6 (Oncology Nursing)  
多職種連携プログラム 6 (看護)

**P72-1 Surveys of support for breast cancer patients who have paid management fees for oncological patient guidance**  
Satomi Yamada (Department of Nursing Nagoya University Hospital)  
**乳癌患者における「がん患者指導管理料」算定時の支援状況**  
山田 里美 (名古屋大学医学部附属病院 看護部)

**P72-2 コロナ病棟から急性期混合病棟へ再編成された部署での看護師のがん看護に対する困難感の調査**  
Nao Kobayashi (Nursing Department, Local independent administrative agency Osaka Municipal Hospital Organization Osaka City General Hospital)  
小林 奈央 (地方独立行政法人 大阪市民病院機構 大阪市立総合医療センター 看護部)

- P72-3** **Changes in the workload of nurses due to the introduction of natural fall control infusion equipment in our hospital**  
 Michie Takahashi (Hakodate Goryoukaku Hospital)  
**当院における自然落下制御式輸液装置導入による看護師の業務負担の変化**  
 高橋 美知枝 (函館五稜郭病院 看護部)
- P72-4** **Verification of skin care methods in high dose administration of thiotepa -From the experience of an adult patient-**  
 Mai Takimoto (Ehime University Hospital pediatrics)  
**チオテパ高用量投与における皮膚障害対策の検証**  
**—成人期に神経芽腫を発症した患者の症状体験から—**  
 滝本 麻衣 (愛媛大学医学部附属病院 小児科)
- P72-5** **Support of decision-making for cancer patients by outpatient nurses in cancer hospital**  
 Rie Irisawa (National Cancer Center Hospital East)  
**がん専門病院外来看護師における意思決定支援の現状調査**  
 入澤 里江 (国立がん研究センター東病院)
- P72-6** **看護師による化学療法静脈穿刺の現状把握と課題～急性期一般病院での院内認定導入の試みを通して**  
 Kanako Kawachi (Tokyo Saiseikai Central Hospital Nursing Department)  
 川地 香奈子 (東京都済生会中央病院 看護部)
- P72-7** **Training and clinical utilization of in-hospital certified nurses -Aiming for higher expertise-**  
 Kaori Uemoto (Hikari Municipal Hikari General Hospital Nursing Department, Outpatient Department)  
**院内認定看護師の育成と臨床活用-より高い専門性を目指して-**  
 上本 かおり (光市立光総合病院 看護部 外来)
- 17:10-17:55 Poster Session 73
- P73** **Medical Case Report 7 (Solid Cancers 1)**  
 ケースレポート7 (その他の固形がん 1)
- P73-1** **High-Grade Serous Ovarian Cancer in a 14 Years Old Teenager- Exceptionally Rare Case Presentation**  
 Santhosh Meedimale (Department of Medical Oncology, IMS, SUM Hospital)
- P73-2** **A case report: Successful perioperative chemotherapy for primary sinonasal Ewing sarcoma**  
 Yusuke Kurioka (Department of Medical Oncology, Kochi Medical School)  
**周術期治療が奏効した副鼻腔Ewing肉腫の一例**  
 栗岡 勇輔 (高知大学 腫瘍内科学講座)
- P73-3** **Two cases of endometrial cancer with perforation early after initiation of pembrolizumab plus lenvatinib**  
 Yukio Yoshida (Division of Oncology and Hematology, Okinawa Chubu Hospital)  
**ペムブロリズマブとレンパチニブ併用療法開始後早期に消化管穿孔を生じた腹膜播種を有する子宮体癌の2例**  
 吉田 幸生 (沖縄県立中部病院 腫瘍・血液内科)

**P73-4 Characteristic genomic status from splenic adenocarcinoma contributed to the prediction of primary site: A case report**  
 Iori Takeda (Medical Student, Yamagata University Faculty of Medicine / Department of cancer genomic testing, Yamagata University)

**脾臓の腺癌病変から得た特徴的なゲノムステータスが原発推定に寄与した1例**  
 竹田 伊織 (山形大学医学部5年 / 山形大学ゲノム管理室)

**P73-5 A cases of high tumor mutation burden cancer with POLE mutation treated with immune checkpoint inhibitor**  
 Shinichi Nishina (Department of Medical Oncology, Kurashiki Central Hospital)

**免疫チェックポイント阻害薬で治療したPOLE変異によるTMB-High固形がんの症例**  
 仁科 慎一 (倉敷中央病院 腫瘍内科)

**P73-6 5-year trend of comprehensive genome profiling test in a regional cancer genomic medicine cooperative hospital**  
 Hiroshi Ariyama (Department of Medical Oncology, Kitakyushu Municipal Medical Center)

**地域のがんゲノム医療連携病院におけるCGP検査の5年間の動向**  
 有山 寛 (北九州市立医療センター 腫瘍内科)

**P73-7 A case of haemophagocytic syndrome and myocarditis after lenvatinib and pembrolizumab therapy for endometrial cancer**  
 Asuna Yumori (Department of Obstetrics and Gynecology, Yamato Municipal Hospital)

**子宮体癌に対するLenvatinib・Pembrolizumab療法施行後に血球貪食症候群及び急性心筋炎を来した1例**  
 祐森 明日菜 (大和市立病院 産婦人科)

**P73-8 CUP successfully treated with lenvatinib and pembrolizumab based on IHC and multi-gene panel testing: a case report**  
 Hiroshi Tsukuda (Department of Medical Oncology, Izumi City General Hospital)

佃 博 (和泉市立総合医療センター 腫瘍内科)

**P73-9 Primary ovarian small cell carcinoma of pulmonary type diagnosed with an ultrasound-guided cervical lymph node biopsy**  
 Daisuke Jingu (Department of Respiratory Medicine, Saka General Hospital)

**エコーガイド下頸部リンパ節穿刺吸引針生検で診断した卵巣原発肺型小細胞癌の1例**  
 神宮 大輔 (坂総合病院 呼吸器科)

17:10-17:55 Poster Session 74

**P74 Medical Case Report 8 (Solid Cancers 2)**  
 ケースレポート 8 (その他の固形がん 2)

**P74-1 CASE OF NASOPHARYNGEAL CARCINOMA WITH INTRACRANIAL EXTENSION PRESENTING AS AN OCCULT PRIMARY WITH BILATERAL NECK MASSES**  
 John Kristoffer M Japzon (Department of Surgery, Cotabato Regional and Medical Center)

**P74-2 Cytokine release syndrome due to treatment with immune checkpoint inhibitor: two case reports**  
 Masanori Takehara (Department of Gastroenterology, Tokushima Red Cross Hospital)

**免疫チェックポイント阻害薬投与によって生じたサイトカイン放出症候群の2例**  
 武原 正典 (徳島赤十字病院 消化器内科)

P74-3	<p><b>A case report of squamous cell carcinoma of hypopharynx with EGFR-amplification treated with off-label afatinib</b></p> <p>Takanobu Shimada (Department of Medical Oncology, Osaka Red Cross Hospital)</p> <p><b>アフアチニブが奏功したEGFR遺伝子増幅を伴う下咽頭扁平上皮癌の1例</b></p> <p>島田 貴信 (大阪赤十字病院 腫瘍内科)</p>
P74-4	<p><b>A Case Report: Immune-related Polymyalgia Rheumatica-like Syndrome after Nivolumab Monotherapy for Tongue Cancer</b></p> <p>Takuya Sato (Department of Medical Oncology, Kochi Medical School)</p> <p><b>舌癌に対するニボルマブ単剤療法後にリウマチ性多発筋痛症様のirAEを発症した1例</b></p> <p>佐藤 拓弥 (高知大学医学部 腫瘍内科学講座)</p>
P74-5	<p><b>A case of Lambert-Eaton myasthenic syndrome associated with oropharyngeal small-cell neuroendocrine carcinoma</b></p> <p>Taiju Ando (Department of Medical Oncology, Fujita Health University Hospital)</p> <p><b>中咽頭原発の小細胞神経内分泌癌に合併したLambert-Eaton筋無力症候群の一例</b></p> <p>安藤 泰樹 (藤田医科大学病院 臨床腫瘍科)</p>
P74-6	<p><b>A case of SMARCA4-deficient anaplastic bladder tumor that was successfully treated with nivolumab</b></p> <p>Ginji Omori (Department of Gastroenterology, Oji General Hospital / Department of Medical Oncology, Sapporo Medical University School of Medicine)</p> <p><b>TUR-BT後に後腹膜に再発したSMARCA4欠損未分化膀胱腫瘍に対し、Nivolumabで加療を行った一例</b></p> <p>大森 銀治 (王子総合病院 / 札幌医科大学 腫瘍内科学講座)</p>
P74-7	<p><b>Acute-onset type 1 diabetes mellitus caused by nivolumab in a patient with mandibular gingival cancer</b></p> <p>Yohei Suzuki (Department of Pharmacy, Tokai University School of Medicine)</p> <p><b>下顎歯肉癌に対するニボルマブにより急性発症した1型糖尿病</b></p> <p>鈴木 洋平 (東海大学医学部付属病院 薬剤部薬剤科)</p>
P74-8	<p><b>A case of skin necrosis not around the injection site after liposomal doxorubicin administration</b></p> <p>Yumiko Shimanuki (Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan)</p> <p><b>リポソーム化ドキソルビシン投与にて刺入部周囲以外に皮膚壊死を認めた一例</b></p> <p>島貫 裕実子 (国立国際医療研究センター病院 薬剤部)</p>
P74-9	<p><b>A case of Takotsubo cardiomyopathy during Lenvatinib treatment for papillary thyroid cancer</b></p> <p>Reiko Kimura-Tsuchiya (Department of Medical Oncology, Fukushima Medical University)</p> <p>木村 礼子 (福島県立医科大学 腫瘍内科)</p>
17:10-17:55 Poster Session 75	
P75	<p>Medical Case Report 9 (Solid Cancers 3)</p> <p>ケースレポート9 (その他の図形がん3)</p>
P75-1	<p><b>A rare case of gastrocnemius metastasis from bladder cancer with durable response to platinum-based chemotherapy</b></p> <p>Jasmin Munchar Elias (Jalan University)</p>

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

- P75-2** **Oropharyngeal Squamous Cell Carcinoma presenting with SSTR overexpression on 68Ga DOTATATE PET scan: A Case Report**  
**Encore**  
 Lorenz Fort E. Revillas (Section of Medical Oncology- Cancer Institute, St Luke's Medical Center-Philippines)
- 
- P75-3** **Neoadjuvant Selective Internal Radiation Therapy and Immune Checkpoint Inhibitors (ICIs) in Potentially Resectable HCC**  
 Po Lin Ooi (Department of Oncology, University Malaya Medical Centre)
- 
- P75-4** **がん化学療法が著効した傍腫瘍神経随伴症候群の2症例**  
 Itaru Satou (Department of Medical Oncology, Ageo Central General Hospital)  
 佐藤 到 (上尾中央総合病院 腫瘍内科)
- 
- P75-5** **Mucosal melanoma with *KIT* mutation and response to imatinib therapy: A case report**  
 Chiaki Kondo (Department of clinical oncology and chemotherapy, Nagoya University Hospital)  
**KIT阻害薬が奏功した粘膜悪性黒色腫の一例**  
 近藤 千晶 (名古屋大学医学部附属病院 化学療法部)
- 
- P75-6** **A case of spinal metastasis from cancer of unknown primary with TMB-H responded to radiotherapy and nivolumab treatment**  
 Hiroaki Takagi (Department of Medical Oncology, Toyama Prefectural Central Hospital)  
**TMB-Hの原発不明癌脊椎転移に対して放射線治療とNivolumab療法が奏効した一例**  
 高木 宏明 (富山県立中央病院 腫瘍内科)
- 
- P75-7** **Gemcitabine plus nab-paclitaxel with osimertinib for locally advanced pancreatic cancer and *EGFR*-mutated lung cancer**  
 Daisuke Shimizu (General Education Center, Kyorin University Hospital)  
**局所進行膵癌とEGFR遺伝子変異陽性IV期肺腺癌の重複癌に対してゲムシタピン+ナブパクリタキセル療法にオシメルチニブを併用し治療し得た一例**  
 清水 大輔 (杏林大学医学部付属病院 総合研修センター)
- 
- P75-8** **A case of metastatic rectal mucosal melanoma with polymyalgia rheumatica induced by nivolumab therapy**  
 Shohei Ueno (Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University / Department of Hematology and Oncology, Japan Community Healthcare Organization Kyushu Hospital)  
**ニボルマブ療法によるリウマチ性多発筋痛症を生じ、休薬後も抗腫瘍効果が維持された転移性直腸粘膜悪性黒色腫の一例**  
 上野 翔平 (九州大学大学院 医学研究院 病態修復内科 / JCHO九州病院 血液・腫瘍内科)
- 
- P75-9** **A case of ampullary cancer indicating good response with PTX**  
 Mai Hayashi (Department of Medical Oncology, Tane General Hospital)  
**十二指腸乳頭部癌に対してPTXが奏効した一例**  
 林 真衣 (多根総合病院 腫瘍内科)

ポスター③ (4号館 3F 438)

11:30-12:15 Poster Session 76

**P76** Cross-sectional Program 1 (Radiation Oncology)  
臓器横断プログラム 1 (放射線治療)

**P76-1** **Modern radiotherapy in treating subependymal giant cell astrocytoma (SEGA): a systematic review of case reports**  
Andre Prawira Putra (Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo Hospital, Indonesia)

**P76-2** **Financial catastrophe in cancer patients having radiotherapy under Indonesia's health insurance scheme: midterm results**  
Andre Prawira Putra (Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo Hospital, Indonesia)

**P76-3** 演題取下

**P76-4** 演題取下

11:30-12:15 Poster Session 77

**P77** Cross-sectional Program 2 (Diagnostic Imaging)  
臓器横断プログラム 2 (画像診断)

**P77-1** **Tertiary lymphoid structure (TLS) and stromal tumor-infiltrating lymphocyte (sTIL) AI-based detection in breast cancer**  
Encore  
Nadezhda Lukashovich (BostonGene, Corp.)

**P77-2** **Efficacy and Safety of Remimazolam Tosilate versus Propofol in Patients Undergoing Gastrointestinal Endoscopy**  
Raenen Liauw (Pelita Harapan University)

11:30-12:15 Poster Session 78

**P78** Cross-sectional Program 3 (Familial and Hereditary Cancer)  
臓器横断プログラム 3 (家族性・遺伝性腫瘍)

**P78-1** **Retrospective analysis of germline pathogenic variants in tumor comprehensive genomic profiling**  
Junji Hiraga (Department of Hematology, Toyota Kosei Hospital)  
当院で施行されたがん遺伝子パネル検査における二次的所見の検討  
平賀 潤二 (豊田厚生病院 血液内科)

**P78-2** **A real-world data of frequency and implication of PGPV based on the results of CGP testing in thoracic cancers**  
Takahiro Fukushima (Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine)  
胸部悪性腫瘍症例におけるCGP検査でのPGPV検出割合とその臨床的意義の考察  
福島 貴大 (慶應義塾大学病院 呼吸器内科)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Poster Experts

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

11:30-12:15 Poster Session 79

**P79** Cross-sectional Program 4 (Epidemiology)  
臓器横断プログラム 4 (がん疫学)

- P79-1** **担がん患者を対象とした深部静脈血栓症に関する後方視的検討**  
Yuya Masuda (Department of Clinical Oncology, Ehime University Graduate School of Medicine / Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine)  
増田 侑也 (愛媛大学医学部附属病院 臨床腫瘍学講座 / 愛媛大学医学部附属病院 第一内科)
- P79-2** **愛媛県院内がん登録2021年分析によるCOVID-19流行下のがん診療における患者行動の推移**  
Makoto Hamada (Department of Cancer Prevention and Epidemiology, Center for Cancer Research, NHO Shikoku Cancer Center / Department of Medical Record Office, NHO Shikoku Cancer Center)  
濱田 信 (国立病院機構四国がんセンター臨床研究センター がん予防・疫学研究部 / 国立病院機構四国がんセンター医療情報管理室)

- P79-3** **Prevalence of MASLD in patients with unresectable solid tumor**  
Toshimitsu Tanaka (Multidisciplinary Treatment Cancer Center, Kurume University Hospital / Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine)  
田中 俊光 (久留米大学病院 / 久留米大学医学部内科学講座現消化器内科部門)

11:30-12:15 Poster Session 80

**P80** Cross-sectional Program 5 (Cancer Prevention)  
臓器横断プログラム 5 (がん予防)

- P80-1** **Dose-response association between alcohol consumption and kidney cancer risk according to glycemc status**  
Joohyun Park (Department of Family Medicine, Korea University College of Medicine, Ansan Hospital)
- P80-2** **Awareness, knowledge, and attitude towards lung cancer among adult patients at a general hospital in Bangladesh**  
Farzana Sultana (Department of Gynecology, Jahurul Islam Medical College, Kishoregonj, Bangladesh.)

11:30-12:15 Poster Session 81

**P81** Cross-sectional Program 6 (Immunobiology and Immunotherapy)  
臓器横断プログラム 6 (免疫)

- P81-1** **Pre-existing autoimmune disease as a risk factor for irAEs in cancer patients receiving immune checkpoint inhibitors**  
Hidetoshi Sumimoto (Department of Medical Oncology, Shiga University of Medical Science Hospital / Cancer Center, Shiga University of Medical Science Hospital / Center for Advanced Medicine Against Cancer, Shiga University of Medical Science)  
**免疫チェックポイント阻害剤投与後の免疫関連有害事象のリスク因子としての自己免疫疾患合併**  
住本 秀敏 (滋賀医科大学附属病院 腫瘍内科 / 滋賀医科大学附属病院腫瘍センター / 滋賀医科大学附属病院先端がん医療センター)



P81-2	<p><b>Correlation between immune-related adverse events and immune checkpoint inhibitor type and combination therapy</b> Masaaki Yanai (Cancer Center, Tottori University Hospital / Department of Respiratory Medicine and Rheumatology, Tottori University Hospital)</p> <p><b>免疫チェックポイント阻害薬の種類および併用薬と免疫関連有害事象発症の関連についての検討</b> 矢内 正晶 (鳥取大学医学部附属病院がんセンター / 鳥取大学医学部附属病院 呼吸器内科・膠原病内科)</p>	Day 1 (Thu)
P81-3	<p><b>Immune-related adverse events (irAE) march during Nivolumab plus Ipilimumab</b> Emiko Mura (Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University)</p> <p><b>Nivolumab+Ipilimumab療法における同時多発の免疫関連有害事象 (irAE マーチ)</b> 村 英美子 (昭和大学医学部 内科学講座腫瘍内科学部門)</p>	Day 2 (Fri)
P81-4	<p><b>Nivolumab-related myositis, myocarditis and cytokine release syndrome: a case report</b> Phamnguyen Quy (Department of Medical Oncology, Kyoto Miniren Central Hospital)</p> <p><b>ニボルマブ関連筋炎、心筋炎にサイトカイン放出症候群を合併した1例</b> Phamnguyen Quy (京都民医連中央病院 腫瘍内科)</p>	Day 3 (Sat)
P81-5	<p><b>Onset and Risk Factors for Interstitial Lung Disease Associated With Immune Checkpoint Inhibitor : A Retrospective Study</b> Takafumi Nonaka (Department of Respiratory Medicine and Rheumatology, Tottori University Hospital)</p> <p><b>免疫チェックポイント阻害薬によるILDの発症状況およびリスク因子についての検討</b> 野中 喬文 (鳥取大学医学部附属病院 呼吸器内科・膠原病内科)</p>	On-demand
P81-6	<p><b>Relationship between onset of irAEs and recurrence during ipilimumab/nivolumab therapy in advanced/metastatic RCC</b> Tetsuya Urasaki (Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research / Department of Genitourinary Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research)</p> <p><b>進行・転移性腎細胞癌におけるイピリムマブ+ニボルマブ併用療法施行時の免疫関連有害事象の発症時期と再発との関連性について</b> 浦崎 哲也 (がん研究会有明病院 総合腫瘍科 / がん研究会有明病院 泌尿器科)</p>	Room 1
17:10-17:55 Poster Session 82		Room 2
P82	<p><b>Cross-sectional Program 7 (Drug Therapy 1)</b> 臓器横断プログラム 7 (薬物療法 1)</p>	Room 3
P82-1	<p><b>Efficacy and Safety of Bone Management Agents Administered at 12 vs. 4 Weeks in Bone Metastases: A Systematic Review</b> Junya Sato (Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences)</p> <p><b>骨転移患者における骨修飾薬の12週投与と4週投与の有効性と安全性: システマチックレビュー</b> 佐藤 淳也 (湘南医療大学 薬学部)</p>	Room 4
P82-2	<p><b>The effect of adjuvant chemotherapy on prognosis among post-operative cancer patients with or without hemodialysis</b> Taisuke Ishii (Division of Health Services Research, National Cancer Center)</p> <p><b>透析合併がん患者の予後と術後補助化学療法の影響改善効果</b> 石井 太祐 (国立がん研究センター 院内がん登録分析室/医療政策部)</p>	Room 5
		Room 6
		Room 7
		Room 8
		Room 9
		Room 10
		Room 11
		Room 12
		Room 13
		Meet the Experts
		Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

- P82-3 Factors associated with severity of immune-checkpoint inhibitors-related colitis in patients with advanced malignancies**  
 Takuya Shimamura (Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University / Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University)  
 島村 拓弥 (佐賀大学医学部附属病院 内科学講座 消化器内科 / 佐賀大学医学部附属病院 内科学講座 血液・呼吸器・腫瘍内科)
- P82-4 Optimal dose of Amrubicin for relapse cases of small cell lung carcinoma and extra-pulmonary neuroendocrine carcinoma**  
 Masashi Takemoto (Department of Pharmacy, Nagoya City University Hospital)  
**再発難治性の小細胞肺癌および肺外神経内分泌癌に対するアムルビシン単独療法の至適用量についての後方視的研究**  
 竹本 将士 (名古屋市立大学病院 薬剤部)
- P82-5 臨床データウェアハウス (DWH) を用いた、ペムブロリズマブの治療効果に関連する因子の探索的検討**  
 Hiromi Matsumoto (Department of Pulmonology, Yokohama City University Graduate School of Medicine)  
 松本 大海 (横浜市立大学大学院医学研究科 呼吸器病学教室)
- P82-6 Background of Patients Considered for Phase I Clinical Trials -Review of the first three years of our department-**  
 Eriko Miyawaki (Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)  
**早期薬剤開発を専門的に行う診療科における第I相治療に組み入れられる患者背景についての検討**  
 宮脇 英里子 (がん研究会有明病院 先端医療開発科)
- 17:10-17:55 Poster Session 83
- P83 Cross-sectional Program 8 (Drug Therapy 2)**  
**臓器横断プログラム 8 (薬物療法 2)**
- P83-1 Exploratory study on resumption of immune checkpoint inhibitors after infection with COVID-19**  
 Ayumi Tsuchiya (Pharmaceutical Department, Center Hospital of the National Center for Global Health and Medicine)  
**COVID-19罹患後の免疫チェックポイント阻害薬の再開状況に関する実態調査**  
 土屋 亜祐美 (国立国際医療研究センター病院 薬剤部)
- P83-2 Predictive factors for the development of drug-induced pneumonitis due to trastuzumab deruxtecan**  
 Yurika Ishii (Department of Respiratory Medicine, Fujita Health University School of Medicine)  
**当院におけるTrastuzumab Deruxtecanによる薬剤性肺炎の検討**  
 石井 友里加 (藤田医科大学 呼吸器内科学)
- P83-3 A retrospective analysis of adrenal insufficiency caused by immune checkpoint inhibitors**  
 Yuya Abe (Department of Medical Oncology, Osaka City General Hospital)  
 阿部 有矢 (大阪市立総合医療センター 腫瘍内科)

**P83-4 Concomitant drug use in patients with microscopic colitis receiving immune checkpoint inhibitors**

Yuki Ikeda (Gastroenterology, Kurashiki Central Hospital)

**免疫チェックポイント阻害薬投与後に発症した顕微鏡的大腸炎と併用薬剤の関連に関する検討**  
池田 有希 (倉敷中央病院 消化器内科)

**P83-5 A case of gastrointestinal stromal tumor responded to pembrolizumab monotherapy**

Yuta Okumura (Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center)

**ペムブロリズマブ単剤療法が奏効したdMMR消化管間質腫瘍の一例**  
奥村 祐太 (九州がんセンター 消化管・腫瘍内科)

**P83-6 Drug treatment based on cancer gene panel test results may prolong the prognosis, so it seems better to test early**

Akihiro Shinji (Department of Medical Oncology, Suwa Red Cross Hospital)

**がん遺伝子パネル検査結果を基にした薬物治療により予後が延長する可能性があり、早めに検査をする方がよさそうだ**  
進士 明宏 (諏訪赤十字病院 腫瘍内科)

17:10-17:55 Poster Session 84

**P84** Cross-sectional Program 9 (Other)  
臓器横断プログラム 9 (その他)

**P84-1 効率的かつ教育的がんゲノム医療エキスパートパネルの運営**

Sadakatsu Ikeda (Department of Precision Cancer Medicine, Tokyo Medical and Dental University Hospital)

池田 貞勝 (東京医科歯科大学病院 がんゲノム診療科)

**P84-2 Clinical results for patients with metastatic bone tumors in the late elderly patients treated with surgery**

Ukei Anazawa (Department of Orthopaedic Surgery, Tokyo Dental College Ichikawa General Hospital)

**当院で転移性骨腫瘍に手術治療を行った後期高齢者の検討**  
穴澤 卯圭 (東京歯科大学市川総合病院 整形外科)

**P84-3 The cell block method in cancer treatment in Fukuoka Wajiro Hospital**

Sayaka Ochi (Department of Clinical Laboratory, Fukuoka Wajiro Hospital)

**当院のがん診療におけるセルブロック法の利用状況**  
越智 早也佳 (福岡和白病院 検査科)

**P84-4 Digital ICA®を応用した細胞分泌物の高感度測定技術**

Yosuke Horiuchi (TOPPAN Holdings Inc.)  
堀内 陽介 (TOPPANホールディングス株式会社)

**P84-5 Run-through test of GenMineTOP in patients with preexisting approved comprehensive genomic profiling tests**

Kanako Hagio (Division of Clinical Cancer Genomics, Hokkaido University Hospital)  
萩尾 加奈子 (北海道大学病院 がん遺伝子診断部)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Poster Experts

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

P84-6

**Anticancer effects of hydrogen**

Yusuke Ichikawa (Department of Research and Development, MiZ Company Limited)

**水素の抗がん作用**

市川 祐介 (MiZ株式会社 研究開発部)

ポスター④ (3号館 3F 3F 通路)

11:30-12:15 Poster Session 85

**P85** Breast Cancer 1 (Early Breast Cancer/Perioperative Treatment 1)  
乳腺 1 (周術期 1)

- P85-1** **Effect of Neoadjuvant Systemic Therapy on the Expressions of Hormone Receptors and HER2/neu among Breast Cancer Patients**  
Laurice T Arayan (Augusto P. Sarmiento Cancer Institute, The Medical City)
- P85-2** **Survival Analysis of HER2 receptor negative and HER2 receptor Low Breast Cancer Patients at a Philippine Hospital**  
Carl Lawrence C. Arenos (Division of Medical Oncology, Department of Medicine, University of the Philippines - Philippine General Hospital)
- P85-3** **The analysis of zinc levels in normal and cancerous breast tissues**  
Chetana Ruangpratheep (Department of Pathology, Phramongkutklao College of Medicine, Bangkok, Thailand)
- P85-4** **Efficacy of Fulvestrant Combined Regimens Compared to Fulvestrant Monotherapy in Breast Neoplasm: A Systematic Review**  
William Sadrakh Kartono (Faculty of Medicine Pelita Harapan University)
- P85-5** **Body Image and Psychological health in Breast Cancer Patients: Regional cancer centre-based study of north-west India**  
Shekhar Goyal (S. P. Medical College & AG of Hospitals / Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University, Noida, Uttar Pradesh, India)
- P85-6** **The Association between Exposure of Bisphenol A (BPA) and Risk of Developing Breast Cancer: Systematic Review**  
Evelyn N Hailianto (Faculty of Medicine, Universitas Pelita Harapan)
- P85-7** **PARP Inhibitors and Chemotherapy in Breast Cancer Patients with BRCA-1 or BRCA-2 Gene Mutations : A Systematic Review**  
Cecilia Arivia (Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University / Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
- P85-8** **The Addition of Abemaciclib in Endocrine Therapy for Early Breast Cancer Patients: A Systematic Review**  
Vanessa G. Christanti (Faculty of Medicine, Pelita Harapan University, Indonesia)
- P85-9** **Analysis of Safety of Abemaciclib as Postoperative Adjuvant Therapy**  
Toru Higuchi (Breast Unit, Japanese Red Cross Saitama Hospital)  
**乳がん術後療法としてのアベマシクリブの安全性の検討**  
樋口 徹 (さいたま赤十字病院 乳腺科)

11:30-12:15 Poster Session 86

**P86** Breast Cancer 2 (Early Breast Cancer/Perioperative Treatment 2)  
乳腺 2 (周術期 2)

- P86-1** **The Association Between Tumor-Infiltrating Lymphocytes (TIL) and Focal Adhesion Kinase (FAK) in Breast Cancer Patients**  
Anak Agung Bagus Putra Indrakusuma (Faculty of Medicine, Udayana University, Bali, Indonesia)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

Day 1 (Thu)	P86-2 <b>Encore</b>	<b>SURVIVAL OUTCOMES OF PATIENTS WITH LOCALLY ADVANCED BREAST CANCER AFTER NEOADJUVANT SYSTEMIC THERAPY</b> Cristina G Domingo (Cancer Institute St Lukes Medical Center Quezon City)
Day 2 (Fri)	P86-3	演題取下
Day 3 (Sat)	P86-4	<b>Effect of Letrozole/Tamoxifen on number &amp; quality of oocytes in breast cancer patients undergoing ivf: systematic review</b> Patricia Angel (Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia)
On-demand	P86-5	演題取下
Room 1	P86-6	<b>NEOADJUVANT THERAPY FOR HER2-POSITIVE ELDERLY BREAST CANCER: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS FROM VIETNAM</b> Anh Dinh (Department of Medical Oncology, Cancer Research and Clinical Trials Center, Vietnam National Cancer Hospital)
Room 2	P86-7	<b>Efficacy of neoadjuvant treatment of HER2-positive breast cancer by ddAC-T combined with anti-HER2 agents in Vietnam</b> Anh Dinh Tran (Department of Oncology & Palliative Care, Hanoi Medical University Hospital / Department of Oncology, Hanoi Medical University)
Room 3	P86-8	<b>Comprehensive analysis of SBS mutational signatures across Indian Breast cancer</b> Pranay Tanwar (Dr. B. R. A.-Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India)
Room 4	P86-9	<b>KEYNOTE-522 regimen (KN522Rx) for early triple negative breast cancer; a retrospective study</b> Kyoko Ikeuchi (Department of Medical Oncology, Hyogo Cancer Center) 池内 香子 (兵庫県立がんセンター 腫瘍内科)
Room 5		
Room 6		
Room 7		11:30-12:15 Poster Session 87
Room 8	<b>P87</b>	Breast Cancer 3 (Early Breast Cancer/Perioperative Treatment 3) 乳腺 3 (周術期 3)
Room 9	P87-1	<b>The Role of Lifestyle Interventions in Preventing Breast Cancer Recurrence : A Systematic Review</b> Chelsie Angelius Liu (Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia)
Room 10	P87-2	<b>Anticancer Activity of Ni (II) Proline Dithiocarbamate Complex on MCF-7 Breast Cancer Cell Lines</b> Yusfitaria Alvina vina (Department of Surgery, Faculty of Medical, Hasanuddin University)
Room 11	P87-3	<b>Analysis of immunohistochemical expression of cyclin B1 (CCNB1) in invasive breast carcinoma tissue</b> Chetana Ruangpratheep (Department of Pathology, Phramongkutklao College of Medicine, Bangkok, Thailand)
Room 12	P87-4 <b>Encore</b>	<b>CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer</b> Jui-Hsiang Hung (Department of Biotechnology, Chia Nan University of Pharmacy and Science, Tainan, Taiwan)
Room 13		
Meet the Experts		
Poster		

P87-5	<b>SF3B1 EXPRESSION PREDICT THE CHEMORESISTANCE IN TRIPLE-NEGATIVE BREAST CANCER</b> I Gede Putu Supadmanaba (Biochemistry Department, Faculty of Medicine, Universitas Udayana)	Day 1 (Thu)
P87-6	<b>Efficacy of Anastrozole in Patients with Breast Cancer: A Systematic Review</b> Elizabeth Elizabeth (Faculty of Medicine, Pelita Harapan University)	Day 2 (Fri)
P87-7	<b>Characteristics and Treatment outcomes of Metaplastic Breast Cancer: A Study at Vietnam National Cancer Hospital</b> Toan Khanh Phan (Department of Oncology, Hanoi Medical University)	Day 3 (Sat)
P87-8	<b>演題取下</b>	On-demand
P87-9	<b>Effect of Pembrolizumab as Neoadjuvant Therapy in Early Triple-Negative Breast Cancer: A Systematic Review</b> Rocky V Sunaryo (Faculty of Medicine, Pelita Harapan University)	Room 1
17:10-17:55 Poster Session 88		
<b>P88</b>	<b>Breast Cancer 4 (Early Breast Cancer/Perioperative Treatment 4)</b> 乳腺 4 (周術期 4)	Room 2
P88-1	<b>The Effects of Exercise on Physical and Psychological in Patients Breast Cancer Surgery: A Systematic Review</b> Diandra A. Karsanto (Faculty of Medicine, Pelita Harapan University.)	Room 3
P88-2	<b>The association of XRCC1 rs25487 polymorphism with luminal and non-luminal breast cancer subtype in Bali</b> Putri Ayu Wulandari (Faculty of Medicine, Udayana University)	Room 4
P88-3	<b>Effectiveness and Safety of Trastuzumab Emtansine in Patients with Breast Cancer: Meta-Analysis of Clinical Trials</b> Charista L. Budiputri (Faculty of Medicine, Pelita Harapan University)	Room 5
P88-4	<b>Safety and Efficacy Abemaciclib in early breast cancer: A Systematic Review</b> Paulina Bellen (Faculty of Medicine, Pelita Harapan University)	Room 6
P88-5	<b>Postoperative breast radiotherapy using image registration of initial PET/CT before NST</b> Kenshiro Shiraishi (Department of Radiology, Teikyo University) 白石 憲史郎 (帝京大学医学部 放射線科)	Room 7
P88-6	<b>A Single-Center Case Series Study on immune related adverse events in Perioperative Triple-Negative Breast Cancer</b> Wataru Kusano (Department of Oncology, Hamanomachi Hospital) <b>周術期トリプルネガティブ乳癌の免疫関連有害事象に関する単施設ケースシリーズ研究</b> 草野 亘 (浜の町病院 腫瘍内科)	Room 8
P88-7	<b>A case report of steroid-resistant irAE colitis associated with neoadjuvant pembrolizumab in early breast cancer</b> Noriko Senda (Department of Breast Surgery, Osaka Red Cross Hospital) 仙田 典子 (大阪赤十字病院 乳腺外科)	Room 9
P88-8	<b>Initial treatment experience with Pegfilgrastim bodypod</b> Yasuhiro Kurumiya (Department of Surgery, Toyota Kosei Hospital) 久留宮 康浩 (豊田厚生病院 外科)	Room 10
		Room 11
		Room 12
		Room 13
		Meet the Poster Experts

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

**P88-9 Experience of Nine Patients with Pembrolizumab for Preoperative Chemotherapy of Breast Cancer**  
 Tsutomu Iwasa (Department of Medical Oncology, Kindai University Faculty of Medicine)  
 岩朝 勤 (近畿大学病院 腫瘍内科)

17:10-17:55 Poster Session 89

**P89 Breast Cancer 5 (Metastatic Breast Cancer 1)**  
 乳腺 5 (転移性 1)

**P89-1 Comparative Effectiveness of T-DM1 and T-DXd in the Treatment of Metastatic Breast Cancer: A Systematic Review of RCTs**  
 Hanifah Angelita (Faculty of Medicine, Pelita Harapan University, Indonesia)

**P89-2 Safety and Efficacy of Ribociclib and Letrozole in HER2-Negative Metastatic Breast Cancer Patient: a Systematic Review**  
 Ghivarell Rizkie Wirawan (Faculty Of Medicine, Pelita Harapan University)

**P89-3 Efficacy of Pembrolizumab in Advanced TNBC: A Systematic Review and Meta-Analysis**  
 Kamila Muyasarah (Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr Sardjito General Hospital, Yogyakarta, Indonesia)

**P89-4 CCDN1 Polymorphism is Associated With Tumor Size in Breast Cancer Patients in Bali**  
 I Gede Krisna Arim Sadeva (Faculty of Medicine, Udayana University)

**P89-5 Impact of SERPINA3 Expression on BRCA: A Prognostic Indicator in Breast Cancer**  
 Mst. Mahmuda Khatun (Biochemistry and Molecular Biology Department, Mawlana Bhashani Science and Technology University)

**P89-6 Clinical Outcomes of Ribociclib/Fulvestrant Combination Therapy in HR-Positive, HER2-Negative Metastatic Breast Cancer**  
 Felicia Bernadette Chandra (Faculty of Medicine, Pelita Harapan University)

**P89-7 The Efficacy of Pembrolizumab Plus Neoadjuvant Treatment for Patients with Triple-Negative Breast Cancer**  
 Cetta M. Saskara (Faculty of Medicine, Pelita Harapan University)

**P89-8 Trousseau syndrome in patients with breast cancer experienced at our hospital**  
 Tokiko Ito (Department of Breast and Endocrine Surgery, Iida Municipal Hospital)  
 伊藤 勲子 (飯田市立病院 乳腺内分泌外科)

17:10-17:55 Poster Session 90

**P90 Breast Cancer 6 (Metastatic Breast Cancer 2)**  
 乳腺 6 (転移性 2)

**P90-1 Efficacy of Talazoraparib in Patients with Germline BRCA-Mutated Advanced Breast Cancer: A Systematic Review**  
 Darren Delvino (Faculty of Medicine, Pelita Harapan University)

**P90-2 BILATERAL EXTRAOCULAR MUSCLE INVOLVEMENT IN METASTATIC BREAST CANCER: A CASE REPORT**  
 Alfred Patrick Dionisio Mina (Augusto P. Sarmiento Cancer Institute - The Medical City)



P90-3	<b>Safety and efficacy of Neratinib in patients with HER 2 Breast Cancer : A Systematic Review</b> Putra Niko Laksamana Oceano Christianto (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)	Day 1 (Thu)
P90-4	<b>Safety and prognosis of combination Abemaciclib with Endocrine therapy in Breast cancer patients : A Meta-analysis</b> William Surya Atmaja (Faculty of Medicine, Pelita Harapan University)	Day 2 (Fri)
P90-5	<b>Efficacy and Safety of Atezolizumab in Patients with Triple Negative Breast Cancer: A Systematic Review</b> Tasya T. Nathania (Faculty of Medicine, Pelita Harapan University)	Day 3 (Sat)
P90-6	<b>Efficacy and Safety of Neratinib and Capecitabine in HER2 Positive Metastatic Breast Cancer: A Systematic Review</b> Emmanuela Wilhelmina Mokalu (Faculty of Medicine, Pelita Harapan University)	On-demand
P90-7	<b>Orthopaedic management for cancer treatment-induced bone loss in postmenopausal breast cancer patients</b> Shohei Tsujino (Department of Orthopaedic Surgery, Saitama Prefectural Cancer Center / Department of Orthopaedic Surgery, Tokyo Medical and Dental University) 辻野 昭平 (埼玉県立がんセンター 整形外科 / 東京医科歯科大学 整形外科)	Room 1
P90-8	<b>Treatment efficacy of S-1 after abemaciclib for hormone receptor-positive HER2-negative metastatic breast cancer</b> Yumiko Koi (Department of Breast Oncology, NHO Kyushu Cancer Center) 厚井 裕三子 (九州がんセンター 乳腺科)	Room 2

17:10-17:55 Poster Session 91

<b>P91</b>	Breast Cancer 7 (Metastatic Breast Cancer 3) 乳腺 7 (転移性 3)	Room 3
P91-1	<b>EFFICACY OF TAMOXIFEN AS A SERM DRUGS IN COMBINED WITH OTHER DRUGS FOR METASTATIC BREAST CANCER: A SYSTEMATIC REVIEW</b> Edeline Huang (Faculty of Medicine, Pelita Harapan University)	Room 4
P91-2	<b>A real world study on efficacy and safety of Tucidinostat after CDK4 and 6 inhibitors in advanced breast cancer</b> Qian Liu (Department of Oncology, first affiliated clinical college of nanjing medical university)	Room 5
P91-3	<b>A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer</b> Ying Pei Hsieh (Department of Medical Oncology, Far Eastern Memorial Hospital)	Room 6
P91-4	<b>A Case of Immune Checkpoint Inhibitor-Associated Myasthenia Gravis in Advanced Breast Cancer</b> Kenta Nio (Department of Oncology, Hamanomachi Hospital) 免疫チェックポイント阻害薬関連重症筋無力症を発症した進行乳癌の一例 二尾 健太 (浜の町病院 腫瘍内科)	Room 7

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

- P91-5** **A single-center retrospective study of 14 patients using olaparib for metastatic breast cancer**  
 Toshiyuki Ishiba (Department of Breast Surgery, Tokyo Medical and Dental University)  
**転移乳癌に対するオラパリブ使用患者 14 例の単施設での後方視的検討**  
 石場 俊之 (東京医科歯科大学 乳腺外科)
- 
- P91-6** **T-DXd for HER2-low expressing cases Breast cancer at our hospital**  
 Eiichiro Noguchi (Department of Breast Surgery, Tokyo Women's Medical University)  
 野口 英一郎 (東京女子医科大学病院 乳腺外科)
- 
- P91-7** **Two cases of Successful Onco-cardiology Management in Breast Cancer Patients with Trastuzumab-induced Cardiomyopathy**  
 Ryo Sakuma (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)  
 佐久間 亮 (国立国際医療研究センター病院 乳腺腫瘍内科)
- 
- P91-8** **Management of ICI in collaboration with other departments**  
 Hitomi Suzuki (Department of Breast Surgery, Ichinomiya Nishi Hospital)  
**他科との連携で挑むICIのマネージメント**  
 鈴木 瞳 (一宮西病院 乳腺外科)

ポスター⑤ (2号館 3F 3F ホワイト)

11:30-12:15 Poster Session 92

**P92** Lung Cancer/ Thoracic Cancer 12 ((Metastatic Non-Small Cell Lung Cancer/Chemotherapy 2)  
呼吸器 12 (非小細胞肺癌/ 転移性 - 化学療法 2)

**P92-1** **The impact of time from diagnosis to chemotherapy on the prognosis in patients with advanced non-small cell lung cancer**

Kenju Ando (Division of Thoracic Oncology, Shizuoka Cancer Center)  
安藤 健樹 (静岡県立静岡がんセンター呼吸器内科)

**P92-2** **Efficacy of bevacizumab for radiation necrosis of brain metastasis in patients with nonsquamous NSCLC**

Daisuke Shibahara (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)  
柴原 大典 (九州大学大学院医学研究院 呼吸器内科学分野)

**P92-3** **A low number of teeth is a poor prognostic factor in patients with advanced non-small cell lung cancer**

Tepei Yamaguchi (Department of Thoracic Oncology, Aichi Cancer Center Hospital)  
山口 哲平 (愛知県がんセンター 呼吸器内科部)

**P92-4** **Clinical Utility of Cancer Genome Profiling (CGP) Test in Thoracic Malignancies**

Yoh Yamaguchi (Department of Thoracic Oncology, National Cancer Center Hospital)  
山口 曜 (国立がん研究センター中央病院 呼吸器内科)

**P92-5** **Effects of low-dose aspirin and statin combination therapy in the patient with unresectable advanced lung adenocarcinoma**

Atsushi Miura (Department of Pharmacy, Saiseikai Kazo Hospital)

**切除不能進行肺腺癌患者における少量アスピリンとスタチン併用療法の効果**

三浦 惇史 (埼玉県済生会加須病院 薬剤部)

11:30-12:15 Poster Session 93

**p93** Medical Case Report 10 (Lung 2)  
ケースレポート 10 (肺 2)

**P93-1** **COEXISTENCE OF TUBERCULOSIS AND LUNG CANCER: A CASE REPORT**

Giang Hoang Pham (Department of Oncology and Haematology, Vinmec International Hospital)

**P93-2** **Metastatic ALK-positive Non-small-cell Lung Cancer with Breast Metastases and JAK2 Positive Myeloproliferative Disease**

Charles Jeffrey L Tan (St. Luke's Medical Center Quezon City)

**P93-3** **A case of immune thrombocytopenic purpura during nivolumab treatment of recurrent postoperative lung cancer patient**

Eika Kudo (Department of thoracic and breast surgery, Oita university)

**肺癌術後再発症例に対するニボルマブ治療中に生じた免疫性血小板減少性紫斑病の1例**

工藤 栄華 (大分大学 呼吸器・乳腺外科)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Poster Experts

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
On-demand  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Meet the Experts  
Poster

- P93-4** **A Case of Lung Adenocarcinoma with EGFR L858R Caused by a Rare 2-Base Deletion-Insertion Mutation Detected by NGS**  
Takumi Fujiwara (Department of Genomic Medicine, Mie University Hospital)  
**遺伝子パネル検査で検出を得た2塩基の欠失挿入によるEGFR遺伝子L858R変異の肺腺がんの症例**  
藤原 拓海 (三重大学医学部附属病院 ゲノム診療科)
- P93-5** **Non-small cell lung cancer with loss of CDKN2A responding to CDK4/6 inhibitor: a case report**  
Chikako Yamauchi (Department of Radiation Oncology, Shiga General Hospital / Center for Genetic medicine, Shiga General Hospital)  
**CDK4/6阻害薬が奏効したCDKN2A lossを有する非小細胞肺癌の一例**  
山内 智香子 (滋賀県立総合病院 放射線治療科 / 滋賀県立総合病院 遺伝子診療センター)
- P93-6** **One case of KRAS G12C detected by Guardant360 despite limited tumour volume**  
Riona Miyawaki (Yamagata University Faculty of Medicine, Department of Medicine)  
**限定的な腫瘍量にもかかわらずGuardant360によりKRAS G12Cを検出した1例**  
宮脇 凜女 (山形大学医学部医学科)
- P93-7** **A Case of EGFR-mutated Lung Cancer That Transformed to Small Cell Lung Cancer with Readministration of Osimertinib**  
Takuo Otsuka (Department of Medical Oncology, Kindai University Faculty of Medicine)  
**小細胞肺癌転化をきたしたEGFR陽性肺癌に対してOsimertinibの再投与をした1例**  
大塚 啄生 (近畿大学医学部内科学 腫瘍内科部門)
- P93-8** **Successful switch to cisplatin-based therapy in a NSCLC patient developing carboplatin-induced hypersensitivity reaction**  
Yuko Nagata (Department of Clinical Pharmacy, National Hospital Organization Fukuoka National Hospital)  
**カルボプラチンによる過敏反応後にシスプラチン併用化学療法を施行・奏効した非小細胞肺癌の一例**  
永田 祐子 (独立行政法人国立病院機構福岡病院 薬剤部)
- P93-9** **Efficacy of gefapixant, a P2X<sub>3</sub> antagonist, for lung cancer-related cough in small cell lung cancer**  
Yoshihisa Ishiura (First department of Internal Medicine, Kansai Medical University)  
**小細胞肺癌の1例における難治咳嗽へのP2X<sub>3</sub>拮抗薬 gefapixantの有効性**  
石浦 嘉久 (関西医科大学総合医療センター 呼吸器内科)
- P93-10** **Readministration of Nivolumab in patient with NSCLC after durable response and 6 years discontinuation due to irAE**  
Toshiaki Takakura (Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Faculty of Medicine)  
**肺臓炎によるNivolumabの中止後6年間の完全奏効を経て増悪した非小細胞肺癌に対してNivolumabの再投与が有効であった1例**  
高倉 敏彰 (和歌山県立医科大学 呼吸器内科・腫瘍内科)
- 17:10-17:55 Poster Session 94
- P94** Medical Case Report 11 (Breast 1)  
ケースレポート 11 (乳腺 1)
- P94-1** **Effective Trastuzumab Deruxtecan Salvage in HER2-Mutant Metastatic Breast Cancer after Pertuzumab- Trastuzumab Failure**  
Ying Pei Hsieh (Department of Medical Oncology, Far Eastern Memorial Hospital)

- P94-2** **TRK inhibitors in CHTOP-NTRK1 fusion-positive advanced breast cancer: a case report**  
Yutaro Yoshitomi (Department of oncology, Center Hospital of National Center for Global Health and Medicine)  
**CHTOP-NTRK1 融合遺伝子陽性進行乳癌に対し TRK 阻害薬で治療した一例**  
吉富 祐太郎 (国立国際医療研究センター病院 乳腺腫瘍内科)
- P94-3** **A case of radiation hepatitis during abemaciclib as adjuvant endocrine therapy for early breast cancer**  
Shogo Nakamoto (Department of Surgery, Tsuyama Chuo Hospital, Department of Breast and Endocrinological Surgery, Okayama University Hospital)  
**乳癌術後補助療法としてアベマシクリブ開始後に生じた薬剤性肝障害と鑑別に難渋した放射線性肝炎の1例**  
中本 翔伍 (津山中央病院 外科, 岡山大学病院 乳腺・内分泌外科)
- P94-4** **Pembrolizumab-induced hemophagocytic lymphohistiocytosis with preoperative systemic chemotherapy for breast cancer**  
Yukino Kawamura (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)  
河村 雪乃 (国立国際医療研究センター病院 乳腺・腫瘍内科)
- P94-5** **A case of non-alcoholic steatohepatitis (NASH) with an unknown fever during breast cancer hormone therapy**  
Yoshika Nagata (Department of Surgery, Kokura Memorial Hospital)  
**乳癌ホルモン療法中に不明熱を来した非アルコール性脂肪肝炎 (NASH) の1例**  
永田 好香 (小倉記念病院 外科)
- P94-6** **A case of bilateral breast cancers co-treated by a PARP inhibitor olaparib with anti-HER2 therapy as adjuvant therapy**  
Hisako Ono (Department of Medical Oncology, Kyoto Daini Red Cross Hospital)  
**乳癌術後補助療法として抗HER2療法とPARP阻害剤の併用療法をおこなった両側乳癌症例**  
小野 寿子 (京都第二赤十字病院 腫瘍内科)
- P94-7** **乳癌骨転移との鑑別を要した掌蹠膿疱症性骨関節炎の一例**  
Risa Oshitani (Ikegami General Hospital, Department of breast surgery)  
大下内 理紗 (池上総合病院 乳腺外科)

17:10-17:55 Poster Session 95

**p95** Medical Case Report 12 (Breast 2)  
ケースレポート 12 (乳腺 2)

- P95-1** **Management and Treatment of Pulmonary Tumor Thrombotic Microangiopathy Associated with Undiagnosed Breast Carcinoma**  
Hidetomo Takakura (Department of Hematology/Oncology, Kita-Harima Medical Center, Ono, Japan)  
高倉 嗣丈 (北播磨総合医療センター 血液腫瘍内科)
- P95-2** **A case of irAE-related adult-onset Still's disease developed during KEYNOTE522 (pembrolizumab+carboplatin+paclitaxel)**  
Koutaro Mekaru (Department of Medical Oncology, Kameda Medical Center)  
**KEYNOTE522 レジメン (キイトルーダ+カルボプラチン+パクリタキセル) 中に発症した IrAE 関連の成人発症 Still 病の一例**  
銘苅 康太郎 (亀田総合病院 腫瘍内科)

**P95-3 A case of triple negative invasive ductal carcinoma of the breast mainly due to gastrointestinal metastatic recurrence**

Yohei Takumi (Department of Thoracic and Breast Surgery, Oita University)

**消化管転移再発を主体としたトリプルネガティブ浸潤性乳癌の1例**

内匠 陽平 (大分大学 呼吸器・乳腺外科)

**P95-4 A case of long-term survival after resection of the isolated cerebellum metastasis from HER2 positive breast cancer**

Eiko Sakata (Department of Breast Surgery, Niigata City General Hospital)

**乳癌術後早期の小脳単発転移切除後長期生存中の1例**

坂田 英子 (新潟市民病院 乳腺外科)

**P95-5 Efficacy of eribulin monotherapy for bone marrow carcinomatosis of breast cancer in a patient with Werner syndrome**

Akihito Fujimi (Department of Hematology, Sapporo Kiyota Hospital)

藤見 章仁 (札幌清田病院 血液内科)

**P95-6 A case of early-stage breast cancer performed pituitary function test 4 years after the onset of pituitary irAE**

Mari Hashimoto (Department of Breast Surgery, Fukushima Medical University Hospital)

**irAE下垂体不全の発症4年経過後に下垂体機能評価を行った乳癌の1例**

橋本 万理 (福島県立医科大学 乳腺外科学講座)

**P95-7 S1 showed remarkable efficacy against recurrent breast cancer with diffuse liver metastasis ; a case report**

Kosuke Sagara (Department of Medical Oncology, Fukuoka Wajiro Hospital)

**進行乳癌、びまん性肝転移に対してS1単剤療法が著効した一例**

相良 浩輔 (福岡和白病院 腫瘍内科)

**P95-8 わずかな術前化学療法によりpCRに至ったHER2陽性乳癌の1例**

Kei Hasegawa (Department of Breast Surgery, Chibanishi General Hospital)

長谷川 圭 (千葉西総合病院 乳腺外科)